CONTROLLED SUB-FENTANYL

Illinois General Assembly - Full Text of SB1773

Select Language

×

The Illinois General Assembly offers the Google Translate™ service for visitor convenience. In no way should it be considered accurate as to the translation of any content herein.

Visitors of the Illinois General Assembly website are encouraged to use other translation services available on the internet.

The English language version is always the official and authoritative version of this website.

NOTE: To return to the original English language version, select the "Show Original" button on the Google Translate™ menu bar at the top of the window.

Choose Language

English

Afrikaans

Albanian

Arabic

Armenian

Azerbaijani

Basque

Bengali

Bosnian

Catalan

Croatian

Czech

Danish

Dutch

Esperanto

Estonian

Filipino

Finnish

French

Galician

Georgian

German

Greek

Gujarati

Haitian Creole

Hausa

Hawaiian

Hebrew

Hindi

Hungarian

Icelandic

Indonesian

Interlingua

Interlingue

Inuktitut

Irish

Italian

Japanese

Javanese

Kannada

Khmer

Korean

Latin

Latvian

Lithuanian

Luxembourgish

Macedonian

Malagasy

Malayalam

Maltese

Maori

Marathi

Myanmar

Nepali

Norwegian

Odia

Pashto

Punjabi

Romanian

Russian

Samoan

Sango

Sanskrit

Sardinian

Sindhi

Sinhala

Slovak

Slovenian

Somali

Southern Sotho

Spanish

Sundanese

Swahili

Swedish

Tamil

Telugu

Thai

Tigrinya

Tonga

Turkish

Ukrainian

Urdu

Vietnamese

Welsh

Xhosa

Yiddish

Yoruba

Zulu

Powered by
Translate

Close

Illinois General Assembly

Top Navigation Bar

Translate

Learn

Select General Assembly

Search the 104th General Assembly

Enter search terms for legislation, members, committees, or schedules.

ILGA.GOV

LEGISLATION & LAWS

Bills & Resolutions

Public Acts

Illinois Compiled Statutes

Illinois Constitution

Search Legislation

Glossary

Guide

Reports & Inquiry

Legislative Reports

Special Reports

FTP Site

Legislator Lookup

Capitol Complex Phone Numbers

Rules & Regulations

Illinois Register

Administrative Rules

Senate

Members

Schedules

Committees

Request for Remote Testimony

Journals

Transcripts

Rules

Audio/Video

FOIA Information

Senate Employment Opportunities

Media Guidelines

House

Members

Schedules

Committees

Submit testimony for House Committees

Journals

Transcripts

Rules

Audio/Video

FOIA Information

House Employment Opportunities

Log In

Mobile Top Bar

Search the 104th General Assembly

Enter keywords to search the Illinois General Assembly website.

Full Text of SB1773

Home

Legislation

Full Text

SB1773 - 104th General Assembly

Bill Status

Full Text

Votes

Witness Slips

Select Menu

Bill Status

Full Text

Votes

Witness Slips

Printer Friendly Version

Introduced

Engrossed

Senate Amendment 001

Senate Amendment 002

Senate Amendment 003

Senate Amendment 004

House Amendment 001

Printer Friendly Version

Introduced

Engrossed

Senate Amendment 001

Senate Amendment 002

Senate Amendment 003

Senate Amendment 004

House Amendment 001

Open PDF

SB1773 Engrossed
LRB104 03029 RLC 13047 b
1

AN ACT concerning criminal law.

2

Be it enacted by the People of the State of Illinois,
3
represented in the General Assembly:

4

Section 5.
The Illinois Controlled Substances Act is
5
amended by changing Sections 102, 204, 206, and 208 and by
6
adding Section 309.1 as follows:

7

(720 ILCS 570/102)

(from Ch. 56 1/2, par. 1102)
8

(Text of Section before amendment by P.A. 103-881
)
9

Sec. 102.
Definitions.
As used in this Act, unless the
10
context otherwise requires:
11

(a) "Addict" means any person who habitually uses any
12
drug, chemical, substance or dangerous drug other than alcohol
13
so as to endanger the public morals, health, safety or welfare
14
or who is so far addicted to the use of a dangerous drug or
15
controlled substance other than alcohol as to have lost the
16
power of self control with reference to his or her addiction.
17

(b) "Administer" means the direct application of a
18
controlled substance, whether by injection, inhalation,
19
ingestion, or any other means, to the body of a patient,
20
research subject, or animal (as defined by the Humane
21
Euthanasia in Animal Shelters Act) by:
22

(1) a practitioner (or, in his or her presence, by his
23

or her authorized agent),

SB1773 Engrossed
- 2 -
LRB104 03029 RLC 13047 b
1

(2) the patient or research subject pursuant to an
2

order, or
3

(3) a euthanasia technician as defined by the Humane
4

Euthanasia in Animal Shelters Act.
5

(c) "Agent" means an authorized person who acts on behalf
6
of or at the direction of a manufacturer, distributor,
7
dispenser, prescriber, or practitioner. It does not include a
8
common or contract carrier, public warehouseman or employee of
9
the carrier or warehouseman.
10

(c-1) "Anabolic Steroids" means any drug or hormonal
11
substance, chemically and pharmacologically related to
12
testosterone (other than estrogens, progestins,
13
corticosteroids, and dehydroepiandrosterone), and includes:
14

(i) 3[beta],17-dihydroxy-5a-androstane,
15

(ii) 3[alpha],17[beta]-dihydroxy-5a-androstane,
16

(iii) 5[alpha]-androstan-3,17-dione,
17

(iv) 1-androstenediol (3[beta],
18

17[beta]-dihydroxy-5[alpha]-androst-1-ene),
19

(v) 1-androstenediol (3[alpha],
20

17[beta]-dihydroxy-5[alpha]-androst-1-ene),
21

(vi) 4-androstenediol
22

(3[beta],17[beta]-dihydroxy-androst-4-ene),
23

(vii) 5-androstenediol
24

(3[beta],17[beta]-dihydroxy-androst-5-ene),
25

(viii) 1-androstenedione
26

([5alpha]-androst-1-en-3,17-dione),

SB1773 Engrossed
- 3 -
LRB104 03029 RLC 13047 b
1

(ix) 4-androstenedione
2

(androst-4-en-3,17-dione),
3

(x) 5-androstenedione
4

(androst-5-en-3,17-dione),
5

(xi) bolasterone (7[alpha],17a-dimethyl-17[beta]-
6

hydroxyandrost-4-en-3-one),
7

(xii) boldenone (17[beta]-hydroxyandrost-
8

1,4,-diene-3-one),
9

(xiii) boldione (androsta-1,4-
10

diene-3,17-dione),
11

(xiv) calusterone (7[beta],17[alpha]-dimethyl-17
12

[beta]-hydroxyandrost-4-en-3-one),
13

(xv) clostebol (4-chloro-17[beta]-
14

hydroxyandrost-4-en-3-one),
15

(xvi) dehydrochloromethyltestosterone (4-chloro-
16

17[beta]-hydroxy-17[alpha]-methyl-
17

androst-1,4-dien-3-one),
18

(xvii) desoxymethyltestosterone
19

(17[alpha]-methyl-5[alpha]
20

-androst-2-en-17[beta]-ol)(a.k.a., madol),
21

(xviii) [delta]1-dihydrotestosterone (a.k.a.
22

'1-testosterone') (17[beta]-hydroxy-
23

5[alpha]-androst-1-en-3-one),
24

(xix) 4-dihydrotestosterone (17[beta]-hydroxy-
25

androstan-3-one),
26

(xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl-

SB1773 Engrossed
- 4 -
LRB104 03029 RLC 13047 b
1

5[alpha]-androstan-3-one),
2

(xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-
3

hydroxyestr-4-ene),
4

(xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl-
5

1[beta],17[beta]-dihydroxyandrost-4-en-3-one),
6

(xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha],
7

17[beta]-dihydroxyandrost-1,4-dien-3-one),
8

(xxiv) furazabol (17[alpha]-methyl-17[beta]-
9

hydroxyandrostano[2,3-c]-furazan),
10

(xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one,
11

(xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy-
12

androst-4-en-3-one),
13

(xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]-
14

dihydroxy-estr-4-en-3-one),
15

(xxviii) mestanolone (17[alpha]-methyl-17[beta]-
16

hydroxy-5-androstan-3-one),
17

(xxix) mesterolone (1amethyl-17[beta]-hydroxy-
18

[5a]-androstan-3-one),
19

(xxx) methandienone (17[alpha]-methyl-17[beta]-
20

hydroxyandrost-1,4-dien-3-one),
21

(xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]-
22

dihydroxyandrost-5-ene),
23

(xxxii) methenolone (1-methyl-17[beta]-hydroxy-
24

5[alpha]-androst-1-en-3-one),
25

(xxxiii) 17[alpha]-methyl-3[beta], 17[beta]-
26

dihydroxy-5a-androstane,

SB1773 Engrossed
- 5 -
LRB104 03029 RLC 13047 b
1

(xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy
2

-5a-androstane,
3

(xxxv) 17[alpha]-methyl-3[beta],17[beta]-
4

dihydroxyandrost-4-ene),
5

(xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-
6

methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one),
7

(xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-
8

hydroxyestra-4,9(10)-dien-3-one),
9

(xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-
10

hydroxyestra-4,9-11-trien-3-one),
11

(xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-
12

hydroxyandrost-4-en-3-one),
13

(xl) mibolerone (7[alpha],17a-dimethyl-17[beta]-
14

hydroxyestr-4-en-3-one),
15

(xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone
16

(17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]-
17

androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl-
18

1-testosterone'),
19

(xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one),
20

(xliii) 19-nor-4-androstenediol (3[beta], 17[beta]-
21

dihydroxyestr-4-ene),
22

(xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]-
23

dihydroxyestr-4-ene),
24

(xlv) 19-nor-5-androstenediol (3[beta], 17[beta]-
25

dihydroxyestr-5-ene),
26

(xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]-

SB1773 Engrossed
- 6 -
LRB104 03029 RLC 13047 b
1

dihydroxyestr-5-ene),
2

(xlvii) 19-nor-4,9(10)-androstadienedione
3

(estra-4,9(10)-diene-3,17-dione),
4

(xlviii) 19-nor-4-androstenedione (estr-4-
5

en-3,17-dione),
6

(xlix) 19-nor-5-androstenedione (estr-5-
7

en-3,17-dione),
8

(l) norbolethone (13[beta], 17a-diethyl-17[beta]-
9

hydroxygon-4-en-3-one),
10

(li) norclostebol (4-chloro-17[beta]-
11

hydroxyestr-4-en-3-one),
12

(lii) norethandrolone (17[alpha]-ethyl-17[beta]-
13

hydroxyestr-4-en-3-one),
14

(liii) normethandrolone (17[alpha]-methyl-17[beta]-
15

hydroxyestr-4-en-3-one),
16

(liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-
17

2-oxa-5[alpha]-androstan-3-one),
18

(lv) oxymesterone (17[alpha]-methyl-4,17[beta]-
19

dihydroxyandrost-4-en-3-one),
20

(lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene-
21

17[beta]-hydroxy-(5[alpha]-androstan-3-one),
22

(lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy-
23

(5[alpha]-androst-2-eno[3,2-c]-pyrazole),
24

(lviii) stenbolone (17[beta]-hydroxy-2-methyl-
25

(5[alpha]-androst-1-en-3-one),
26

(lix) testolactone (13-hydroxy-3-oxo-13,17-

SB1773 Engrossed
- 7 -
LRB104 03029 RLC 13047 b
1

secoandrosta-1,4-dien-17-oic
2

acid lactone),
3

(lx) testosterone (17[beta]-hydroxyandrost-
4

4-en-3-one),
5

(lxi) tetrahydrogestrinone (13[beta], 17[alpha]-
6

diethyl-17[beta]-hydroxygon-
7

4,9,11-trien-3-one),
8

(lxii) trenbolone (17[beta]-hydroxyestr-4,9,
9

11-trien-3-one).
10

Any person who is otherwise lawfully in possession of an
11
anabolic steroid, or who otherwise lawfully manufactures,
12
distributes, dispenses, delivers, or possesses with intent to
13
deliver an anabolic steroid, which anabolic steroid is
14
expressly intended for and lawfully allowed to be administered
15
through implants to livestock or other nonhuman species, and
16
which is approved by the Secretary of Health and Human
17
Services for such administration, and which the person intends
18
to administer or have administered through such implants,
19
shall not be considered to be in unauthorized possession or to
20
unlawfully manufacture, distribute, dispense, deliver, or
21
possess with intent to deliver such anabolic steroid for
22
purposes of this Act.
23

(d) "Administration" means the Drug Enforcement
24
Administration, United States Department of Justice, or its
25
successor agency.
26

(d-5) "Clinical Director, Prescription Monitoring Program"

SB1773 Engrossed
- 8 -
LRB104 03029 RLC 13047 b
1
means a Department of Human Services administrative employee
2
licensed to either prescribe or dispense controlled substances
3
who shall run the clinical aspects of the Department of Human
4
Services Prescription Monitoring Program and its Prescription
5
Information Library.
6

(d-10) "Compounding" means the preparation and mixing of
7
components, excluding flavorings, (1) as the result of a
8
prescriber's prescription drug order or initiative based on
9
the prescriber-patient-pharmacist relationship in the course
10
of professional practice or (2) for the purpose of, or
11
incident to, research, teaching, or chemical analysis and not
12
for sale or dispensing. "Compounding" includes the preparation
13
of drugs or devices in anticipation of receiving prescription
14
drug orders based on routine, regularly observed dispensing
15
patterns. Commercially available products may be compounded
16
for dispensing to individual patients only if both of the
17
following conditions are met: (i) the commercial product is
18
not reasonably available from normal distribution channels in
19
a timely manner to meet the patient's needs and (ii) the
20
prescribing practitioner has requested that the drug be
21
compounded.
22

(e) "Control" means to add a drug or other substance, or
23
immediate precursor, to a Schedule whether by transfer from
24
another Schedule or otherwise.
25

(f) "Controlled Substance" means (i) a drug, substance,
26
immediate precursor, or synthetic drug in the Schedules of

SB1773 Engrossed
- 9 -
LRB104 03029 RLC 13047 b
1
Article II of this Act or (ii) a drug or other substance, or
2
immediate precursor, designated as a controlled substance by
3
the Department through administrative rule. The term does not
4
include distilled spirits, wine, malt beverages, or tobacco,
5
as those terms are defined or used in the Liquor Control Act of
6
1934 and the Tobacco Products Tax Act of 1995.
7

(f-5) "Controlled substance analog" means a substance:
8

(1) the chemical structure of which is substantially
9

similar to the chemical structure of a controlled
10

substance in Schedule I or II;
11

(2) which has a stimulant, depressant, or
12

hallucinogenic effect on the central nervous system that
13

is substantially similar to or greater than the stimulant,
14

depressant, or hallucinogenic effect on the central
15

nervous system of a controlled substance in Schedule I or
16

II; or
17

(3) with respect to a particular person, which such
18

person represents or intends to have a stimulant,
19

depressant, or hallucinogenic effect on the central
20

nervous system that is substantially similar to or greater
21

than the stimulant, depressant, or hallucinogenic effect
22

on the central nervous system of a controlled substance in
23

Schedule I or II.
24

(g) "Counterfeit substance" means a controlled substance,
25
which, or the container or labeling of which, without
26
authorization bears the trademark, trade name, or other

SB1773 Engrossed
- 10 -
LRB104 03029 RLC 13047 b
1
identifying mark, imprint, number or device, or any likeness
2
thereof, of a manufacturer, distributor, or dispenser other
3
than the person who in fact manufactured, distributed, or
4
dispensed the substance.
5

(h) "Deliver" or "delivery" means the actual, constructive
6
or attempted transfer of possession of a controlled substance,
7
with or without consideration, whether or not there is an
8
agency relationship. "Deliver" or "delivery" does not include
9
the donation of drugs to the extent permitted under the
10
Illinois Drug Reuse Opportunity Program Act.
11

(i) "Department" means the Illinois Department of Human
12
Services (as successor to the Department of Alcoholism and
13
Substance Abuse) or its successor agency.
14

(j) (Blank).
15

(k) "Department of Corrections" means the Department of
16
Corrections of the State of Illinois or its successor agency.
17

(l) "Department of Financial and Professional Regulation"
18
means the Department of Financial and Professional Regulation
19
of the State of Illinois or its successor agency.
20

(m) "Depressant" means any drug that (i) causes an overall
21
depression of central nervous system functions, (ii) causes
22
impaired consciousness and awareness, and (iii) can be
23
habit-forming or lead to a substance abuse problem, including,
24
but not limited to, alcohol, cannabis and its active
25
principles and their analogs, benzodiazepines and their
26
analogs, barbiturates and their analogs, opioids (natural and

SB1773 Engrossed
- 11 -
LRB104 03029 RLC 13047 b
1
synthetic) and their analogs, and chloral hydrate and similar
2
sedative hypnotics.
3

(n) (Blank).
4

(o) "Director" means the Director of the Illinois State
5
Police or his or her designated agents.
6

(p) "Dispense" means to deliver a controlled substance to
7
an ultimate user or research subject by or pursuant to the
8
lawful order of a prescriber, including the prescribing,
9
administering, packaging, labeling, or compounding necessary
10
to prepare the substance for that delivery.
11

(q) "Dispenser" means a practitioner who dispenses.
12

(r) "Distribute" means to deliver, other than by
13
administering or dispensing, a controlled substance.
14

(s) "Distributor" means a person who distributes.
15

(t) "Drug" means (1) substances recognized as drugs in the
16
official United States Pharmacopoeia, Official Homeopathic
17
Pharmacopoeia of the United States, or official National
18
Formulary, or any supplement to any of them; (2) substances
19
intended for use in diagnosis, cure, mitigation, treatment, or
20
prevention of disease in man or animals; (3) substances (other
21
than food) intended to affect the structure of any function of
22
the body of man or animals and (4) substances intended for use
23
as a component of any article specified in clause (1), (2), or
24
(3) of this subsection. It does not include devices or their
25
components, parts, or accessories.
26

(t-3) "Electronic health record" or "EHR" means an

SB1773 Engrossed
- 12 -
LRB104 03029 RLC 13047 b
1
electronic record of health-related information on an
2
individual that is created, gathered, managed, and consulted
3
by authorized health care clinicians and staff.
4

(t-3.5) "Electronic health record system" or "EHR system"
5
means any computer-based system or combination of federally
6
certified Health IT Modules (defined at 42 CFR 170.102 or its
7
successor) used as a repository for electronic health records
8
and accessed or updated by a prescriber or authorized
9
surrogate in the ordinary course of his or her medical
10
practice. For purposes of connecting to the Prescription
11
Information Library maintained by the Bureau of Pharmacy and
12
Clinical Support Systems or its successor, an EHR system may
13
connect to the Prescription Information Library directly or
14
through all or part of a computer program or system that is a
15
federally certified Health IT Module maintained by a third
16
party and used by the EHR system to secure access to the
17
database.
18

(t-4) "Emergency medical services personnel" has the
19
meaning ascribed to it in the Emergency Medical Services (EMS)
20
Systems Act.
21

(t-5) "Euthanasia agency" means an entity certified by the
22
Department of Financial and Professional Regulation for the
23
purpose of animal euthanasia that holds an animal control
24
facility license or animal shelter license under the Animal
25
Welfare Act. A euthanasia agency is authorized to purchase,
26
store, possess, and utilize Schedule II nonnarcotic and

SB1773 Engrossed
- 13 -
LRB104 03029 RLC 13047 b
1
Schedule III nonnarcotic drugs for the sole purpose of animal
2
euthanasia.
3

(t-10) "Euthanasia drugs" means Schedule II or Schedule
4
III substances (nonnarcotic controlled substances) that are
5
used by a euthanasia agency for the purpose of animal
6
euthanasia.
7

(u) "Good faith" means the prescribing or dispensing of a
8
controlled substance by a practitioner in the regular course
9
of professional treatment to or for any person who is under his
10
or her treatment for a pathology or condition other than that
11
individual's physical or psychological dependence upon or
12
addiction to a controlled substance, except as provided
13
herein: and application of the term to a pharmacist shall mean
14
the dispensing of a controlled substance pursuant to the
15
prescriber's order which in the professional judgment of the
16
pharmacist is lawful. The pharmacist shall be guided by
17
accepted professional standards, including, but not limited
18
to, the following, in making the judgment:
19

(1) lack of consistency of prescriber-patient
20

relationship,
21

(2) frequency of prescriptions for same drug by one
22

prescriber for large numbers of patients,
23

(3) quantities beyond those normally prescribed,
24

(4) unusual dosages (recognizing that there may be
25

clinical circumstances where more or less than the usual
26

dose may be used legitimately),

SB1773 Engrossed
- 14 -
LRB104 03029 RLC 13047 b
1

(5) unusual geographic distances between patient,
2

pharmacist and prescriber,
3

(6) consistent prescribing of habit-forming drugs.
4

(u-0.5) "Hallucinogen" means a drug that causes markedly
5
altered sensory perception leading to hallucinations of any
6
type.
7

(u-1) "Home infusion services" means services provided by
8
a pharmacy in compounding solutions for direct administration
9
to a patient in a private residence, long-term care facility,
10
or hospice setting by means of parenteral, intravenous,
11
intramuscular, subcutaneous, or intraspinal infusion.
12

(u-5) "Illinois State Police" means the Illinois State
13
Police or its successor agency.
14

(v) "Immediate precursor" means a substance:
15

(1) which the Department has found to be and by rule
16

designated as being a principal compound used, or produced
17

primarily for use, in the manufacture of a controlled
18

substance;
19

(2) which is an immediate chemical intermediary used
20

or likely to be used in the manufacture of such controlled
21

substance; and
22

(3) the control of which is necessary to prevent,
23

curtail or limit the manufacture of such controlled
24

substance.
25

(w) "Instructional activities" means the acts of teaching,
26
educating or instructing by practitioners using controlled

SB1773 Engrossed
- 15 -
LRB104 03029 RLC 13047 b
1
substances within educational facilities approved by the State
2
Board of Education or its successor agency.
3

(x) "Local authorities" means a duly organized State,
4
County or Municipal peace unit or police force.
5

(y) "Look-alike substance" means a substance, other than a
6
controlled substance which (1) by overall dosage unit
7
appearance, including shape, color, size, markings or lack
8
thereof, taste, consistency, or any other identifying physical
9
characteristic of the substance, would lead a reasonable
10
person to believe that the substance is a controlled
11
substance, or (2) is expressly or impliedly represented to be
12
a controlled substance or is distributed under circumstances
13
which would lead a reasonable person to believe that the
14
substance is a controlled substance. For the purpose of
15
determining whether the representations made or the
16
circumstances of the distribution would lead a reasonable
17
person to believe the substance to be a controlled substance
18
under this clause (2) of subsection (y), the court or other
19
authority may consider the following factors in addition to
20
any other factor that may be relevant:
21

(a) statements made by the owner or person in control
22

of the substance concerning its nature, use or effect;
23

(b) statements made to the buyer or recipient that the
24

substance may be resold for profit;
25

(c) whether the substance is packaged in a manner
26

normally used for the illegal distribution of controlled

SB1773 Engrossed
- 16 -
LRB104 03029 RLC 13047 b
1

substances;
2

(d) whether the distribution or attempted distribution
3

included an exchange of or demand for money or other
4

property as consideration, and whether the amount of the
5

consideration was substantially greater than the
6

reasonable retail market value of the substance.
7

Clause (1) of this subsection (y) shall not apply to a
8
noncontrolled substance in its finished dosage form that was
9
initially introduced into commerce prior to the initial
10
introduction into commerce of a controlled substance in its
11
finished dosage form which it may substantially resemble.
12

Nothing in this subsection (y) prohibits the dispensing or
13
distributing of noncontrolled substances by persons authorized
14
to dispense and distribute controlled substances under this
15
Act, provided that such action would be deemed to be carried
16
out in good faith under subsection (u) if the substances
17
involved were controlled substances.
18

Nothing in this subsection (y) or in this Act prohibits
19
the manufacture, preparation, propagation, compounding,
20
processing, packaging, advertising or distribution of a drug
21
or drugs by any person registered pursuant to Section 510 of
22
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
23

(y-1) "Mail-order pharmacy" means a pharmacy that is
24
located in a state of the United States that delivers,
25
dispenses or distributes, through the United States Postal
26
Service or other common carrier, to Illinois residents, any

SB1773 Engrossed
- 17 -
LRB104 03029 RLC 13047 b
1
substance which requires a prescription.
2

(z) "Manufacture" means the production, preparation,
3
propagation, compounding, conversion or processing of a
4
controlled substance other than methamphetamine, either
5
directly or indirectly, by extraction from substances of
6
natural origin, or independently by means of chemical
7
synthesis, or by a combination of extraction and chemical
8
synthesis, and includes any packaging or repackaging of the
9
substance or labeling of its container, except that this term
10
does not include:
11

(1) by an ultimate user, the preparation or
12

compounding of a controlled substance for his or her own
13

use;
14

(2) by a practitioner, or his or her authorized agent
15

under his or her supervision, the preparation,
16

compounding, packaging, or labeling of a controlled
17

substance:
18

(a) as an incident to his or her administering or
19

dispensing of a controlled substance in the course of
20

his or her professional practice; or
21

(b) as an incident to lawful research, teaching or
22

chemical analysis and not for sale; or
23

(3) the packaging, repackaging, or labeling of drugs
24

only to the extent permitted under the Illinois Drug Reuse
25

Opportunity Program Act.
26

(z-1) (Blank).

SB1773 Engrossed
- 18 -
LRB104 03029 RLC 13047 b
1

(z-5) "Medication shopping" means the conduct prohibited
2
under subsection (a) of Section 314.5 of this Act.
3

(z-10) "Mid-level practitioner" means (i) a physician
4
assistant who has been delegated authority to prescribe
5
through a written delegation of authority by a physician
6
licensed to practice medicine in all of its branches, in
7
accordance with Section 7.5 of the Physician Assistant
8
Practice Act of 1987, (ii) an advanced practice registered
9
nurse who has been delegated authority to prescribe through a
10
written delegation of authority by a physician licensed to
11
practice medicine in all of its branches or by a podiatric
12
physician, in accordance with Section 65-40 of the Nurse
13
Practice Act, (iii) an advanced practice registered nurse
14
certified as a nurse practitioner, nurse midwife, or clinical
15
nurse specialist who has been granted authority to prescribe
16
by a hospital affiliate in accordance with Section 65-45 of
17
the Nurse Practice Act, (iv) an animal euthanasia agency, or
18
(v) a prescribing psychologist.
19

(aa) "Narcotic drug" means any of the following, whether
20
produced directly or indirectly by extraction from substances
21
of vegetable origin, or independently by means of chemical
22
synthesis, or by a combination of extraction and chemical
23
synthesis:
24

(1) opium, opiates, derivatives of opium and opiates,
25

including their isomers, esters, ethers, salts, and salts
26

of isomers, esters, and ethers, whenever the existence of

SB1773 Engrossed
- 19 -
LRB104 03029 RLC 13047 b
1

such isomers, esters, ethers, and salts is possible within
2

the specific chemical designation; however the term
3

"narcotic drug" does not include the isoquinoline
4

alkaloids of opium;
5

(2) (blank);
6

(3) opium poppy and poppy straw;
7

(4) coca leaves, except coca leaves and extracts of
8

coca leaves from which substantially all of the cocaine
9

and ecgonine, and their isomers, derivatives and salts,
10

have been removed;
11

(5) cocaine, its salts, optical and geometric isomers,
12

and salts of isomers;
13

(6) ecgonine, its derivatives, their salts, isomers,
14

and salts of isomers;
15

(7) any compound, mixture, or preparation which
16

contains any quantity of any of the substances referred to
17

in subparagraphs (1) through (6).
18

(bb) "Nurse" means a registered nurse licensed under the
19
Nurse Practice Act.
20

(cc) (Blank).
21

(dd) "Opiate" means any substance having an addiction
22
forming or addiction sustaining liability similar to morphine
23
or being capable of conversion into a drug having addiction
24
forming or addiction sustaining liability.
25

(ee) "Opium poppy" means the plant of the species Papaver
26
somniferum L., except its seeds.

SB1773 Engrossed
- 20 -
LRB104 03029 RLC 13047 b
1

(ee-5) "Oral dosage" means a tablet, capsule, elixir, or
2
solution or other liquid form of medication intended for
3
administration by mouth, but the term does not include a form
4
of medication intended for buccal, sublingual, or transmucosal
5
administration.
6

(ff) "Parole and Pardon Board" means the Parole and Pardon
7
Board of the State of Illinois or its successor agency.
8

(gg) "Person" means any individual, corporation,
9
mail-order pharmacy, government or governmental subdivision or
10
agency, business trust, estate, trust, partnership or
11
association, or any other entity.
12

(hh) "Pharmacist" means any person who holds a license or
13
certificate of registration as a registered pharmacist, a
14
local registered pharmacist or a registered assistant
15
pharmacist under the Pharmacy Practice Act.
16

(ii) "Pharmacy" means any store, ship or other place in
17
which pharmacy is authorized to be practiced under the
18
Pharmacy Practice Act.
19

(ii-5) "Pharmacy shopping" means the conduct prohibited
20
under subsection (b) of Section 314.5 of this Act.
21

(ii-10) "Physician" (except when the context otherwise
22
requires) means a person licensed to practice medicine in all
23
of its branches.
24

(jj) "Poppy straw" means all parts, except the seeds, of
25
the opium poppy, after mowing.
26

(kk) "Practitioner" means a physician licensed to practice

SB1773 Engrossed
- 21 -
LRB104 03029 RLC 13047 b
1
medicine in all its branches, dentist, optometrist, podiatric
2
physician, veterinarian, scientific investigator, pharmacist,
3
physician assistant, advanced practice registered nurse,
4
licensed practical nurse, registered nurse, emergency medical
5
services personnel, hospital, laboratory, or pharmacy, or
6
other person licensed, registered, or otherwise lawfully
7
permitted by the United States or this State to distribute,
8
dispense, conduct research with respect to, administer or use
9
in teaching or chemical analysis, a controlled substance in
10
the course of professional practice or research.
11

(ll) "Pre-printed prescription" means a written
12
prescription upon which the designated drug has been indicated
13
prior to the time of issuance; the term does not mean a written
14
prescription that is individually generated by machine or
15
computer in the prescriber's office.
16

(mm) "Prescriber" means a physician licensed to practice
17
medicine in all its branches, dentist, optometrist,
18
prescribing psychologist licensed under Section 4.2 of the
19
Clinical Psychologist Licensing Act with prescriptive
20
authority delegated under Section 4.3 of the Clinical
21
Psychologist Licensing Act, podiatric physician, or
22
veterinarian who issues a prescription, a physician assistant
23
who issues a prescription for a controlled substance in
24
accordance with Section 303.05, a written delegation, and a
25
written collaborative agreement required under Section 7.5 of
26
the Physician Assistant Practice Act of 1987, an advanced

SB1773 Engrossed
- 22 -
LRB104 03029 RLC 13047 b
1
practice registered nurse with prescriptive authority
2
delegated under Section 65-40 of the Nurse Practice Act and in
3
accordance with Section 303.05, a written delegation, and a
4
written collaborative agreement under Section 65-35 of the
5
Nurse Practice Act, an advanced practice registered nurse
6
certified as a nurse practitioner, nurse midwife, or clinical
7
nurse specialist who has been granted authority to prescribe
8
by a hospital affiliate in accordance with Section 65-45 of
9
the Nurse Practice Act and in accordance with Section 303.05,
10
or an advanced practice registered nurse certified as a nurse
11
practitioner, nurse midwife, or clinical nurse specialist who
12
has full practice authority pursuant to Section 65-43 of the
13
Nurse Practice Act.
14

(nn) "Prescription" means a written, facsimile, or oral
15
order, or an electronic order that complies with applicable
16
federal requirements, of a physician licensed to practice
17
medicine in all its branches, dentist, podiatric physician or
18
veterinarian for any controlled substance, of an optometrist
19
in accordance with Section 15.1 of the Illinois Optometric
20
Practice Act of 1987, of a prescribing psychologist licensed
21
under Section 4.2 of the Clinical Psychologist Licensing Act
22
with prescriptive authority delegated under Section 4.3 of the
23
Clinical Psychologist Licensing Act, of a physician assistant
24
for a controlled substance in accordance with Section 303.05,
25
a written delegation, and a written collaborative agreement
26
required under Section 7.5 of the Physician Assistant Practice

SB1773 Engrossed
- 23 -
LRB104 03029 RLC 13047 b
1
Act of 1987, of an advanced practice registered nurse with
2
prescriptive authority delegated under Section 65-40 of the
3
Nurse Practice Act who issues a prescription for a controlled
4
substance in accordance with Section 303.05, a written
5
delegation, and a written collaborative agreement under
6
Section 65-35 of the Nurse Practice Act, of an advanced
7
practice registered nurse certified as a nurse practitioner,
8
nurse midwife, or clinical nurse specialist who has been
9
granted authority to prescribe by a hospital affiliate in
10
accordance with Section 65-45 of the Nurse Practice Act and in
11
accordance with Section 303.05 when required by law, or of an
12
advanced practice registered nurse certified as a nurse
13
practitioner, nurse midwife, or clinical nurse specialist who
14
has full practice authority pursuant to Section 65-43 of the
15
Nurse Practice Act.
16

(nn-5) "Prescription Information Library" (PIL) means an
17
electronic library that contains reported controlled substance
18
data.
19

(nn-10) "Prescription Monitoring Program" (PMP) means the
20
entity that collects, tracks, and stores reported data on
21
controlled substances and select drugs pursuant to Section
22
316.
23

(oo) "Production" or "produce" means manufacture,
24
planting, cultivating, growing, or harvesting of a controlled
25
substance other than methamphetamine.
26

(pp) "Registrant" means every person who is required to

SB1773 Engrossed
- 24 -
LRB104 03029 RLC 13047 b
1
register under Section 302 of this Act.
2

(qq) "Registry number" means the number assigned to each
3
person authorized to handle controlled substances under the
4
laws of the United States and of this State.
5

(qq-5) "Secretary" means, as the context requires, either
6
the Secretary of the Department or the Secretary of the
7
Department of Financial and Professional Regulation, and the
8
Secretary's designated agents.
9

(rr) "State" includes the State of Illinois and any state,
10
district, commonwealth, territory, insular possession thereof,
11
and any area subject to the legal authority of the United
12
States of America.
13

(rr-5) "Stimulant" means any drug that (i) causes an
14
overall excitation of central nervous system functions, (ii)
15
causes impaired consciousness and awareness, and (iii) can be
16
habit-forming or lead to a substance abuse problem, including,
17
but not limited to, amphetamines and their analogs,
18
methylphenidate and its analogs, cocaine, and phencyclidine
19
and its analogs.
20

(rr-10) "Synthetic drug" includes, but is not limited to,
21
any synthetic cannabinoids or piperazines or any synthetic
22
cathinones as provided for in Schedule I.
23

(ss) "Ultimate user" means a person who lawfully possesses
24
a controlled substance for his or her own use or for the use of
25
a member of his or her household or for administering to an
26
animal owned by him or her or by a member of his or her

SB1773 Engrossed
- 25 -
LRB104 03029 RLC 13047 b
1
household.
2
(Source: P.A. 101-666, eff. 1-1-22; 102-389, eff. 1-1-22;
3
102-538, eff. 8-20-21; 102-813, eff. 5-13-22.)

4

(Text of Section after amendment by P.A. 103-881
)
5

Sec. 102.
Definitions.
As used in this Act, unless the
6
context otherwise requires:
7

(a) "Person with a substance use disorder" means any
8
person who has a substance use disorder diagnosis defined as a
9
spectrum of persistent and recurring problematic behavior that
10
encompasses 10 separate classes of drugs: alcohol; caffeine;
11
cannabis; hallucinogens; inhalants; opioids; sedatives,
12
hypnotics and anxiolytics; stimulants; and tobacco; and other
13
unknown substances leading to clinically significant
14
impairment or distress.
15

(b) "Administer" means the direct application of a
16
controlled substance, whether by injection, inhalation,
17
ingestion, or any other means, to the body of a patient,
18
research subject, or animal (as defined by the Humane
19
Euthanasia in Animal Shelters Act) by:
20

(1) a practitioner (or, in his or her presence, by his
21

or her authorized agent),
22

(2) the patient or research subject pursuant to an
23

order, or
24

(3) a euthanasia technician as defined by the Humane
25

Euthanasia in Animal Shelters Act.

SB1773 Engrossed
- 26 -
LRB104 03029 RLC 13047 b
1

(c) "Agent" means an authorized person who acts on behalf
2
of or at the direction of a manufacturer, distributor,
3
dispenser, prescriber, or practitioner. It does not include a
4
common or contract carrier, public warehouseman or employee of
5
the carrier or warehouseman.
6

(c-1) "Anabolic Steroids" means any drug or hormonal
7
substance, chemically and pharmacologically related to
8
testosterone (other than estrogens, progestins,
9
corticosteroids, and dehydroepiandrosterone), and includes:
10

(i) 3[beta],17-dihydroxy-5a-androstane,
11

(ii) 3[alpha],17[beta]-dihydroxy-5a-androstane,
12

(iii) 5[alpha]-androstan-3,17-dione,
13

(iv) 1-androstenediol (3[beta],
14

17[beta]-dihydroxy-5[alpha]-androst-1-ene),
15

(v) 1-androstenediol (3[alpha],
16

17[beta]-dihydroxy-5[alpha]-androst-1-ene),
17

(vi) 4-androstenediol
18

(3[beta],17[beta]-dihydroxy-androst-4-ene),
19

(vii) 5-androstenediol
20

(3[beta],17[beta]-dihydroxy-androst-5-ene),
21

(viii) 1-androstenedione
22

([5alpha]-androst-1-en-3,17-dione),
23

(ix) 4-androstenedione
24

(androst-4-en-3,17-dione),
25

(x) 5-androstenedione
26

(androst-5-en-3,17-dione),

SB1773 Engrossed
- 27 -
LRB104 03029 RLC 13047 b
1

(xi) bolasterone (7[alpha],17a-dimethyl-17[beta]-
2

hydroxyandrost-4-en-3-one),
3

(xii) boldenone (17[beta]-hydroxyandrost-
4

1,4,-diene-3-one),
5

(xiii) boldione (androsta-1,4-
6

diene-3,17-dione),
7

(xiv) calusterone (7[beta],17[alpha]-dimethyl-17
8

[beta]-hydroxyandrost-4-en-3-one),
9

(xv) clostebol (4-chloro-17[beta]-
10

hydroxyandrost-4-en-3-one),
11

(xvi) dehydrochloromethyltestosterone (4-chloro-
12

17[beta]-hydroxy-17[alpha]-methyl-
13

androst-1,4-dien-3-one),
14

(xvii) desoxymethyltestosterone
15

(17[alpha]-methyl-5[alpha]
16

-androst-2-en-17[beta]-ol)(a.k.a., madol),
17

(xviii) [delta]1-dihydrotestosterone (a.k.a.
18

'1-testosterone') (17[beta]-hydroxy-
19

5[alpha]-androst-1-en-3-one),
20

(xix) 4-dihydrotestosterone (17[beta]-hydroxy-
21

androstan-3-one),
22

(xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl-
23

5[alpha]-androstan-3-one),
24

(xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-
25

hydroxyestr-4-ene),
26

(xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl-

SB1773 Engrossed
- 28 -
LRB104 03029 RLC 13047 b
1

1[beta],17[beta]-dihydroxyandrost-4-en-3-one),
2

(xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha],
3

17[beta]-dihydroxyandrost-1,4-dien-3-one),
4

(xxiv) furazabol (17[alpha]-methyl-17[beta]-
5

hydroxyandrostano[2,3-c]-furazan),
6

(xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one,
7

(xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy-
8

androst-4-en-3-one),
9

(xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]-
10

dihydroxy-estr-4-en-3-one),
11

(xxviii) mestanolone (17[alpha]-methyl-17[beta]-
12

hydroxy-5-androstan-3-one),
13

(xxix) mesterolone (1amethyl-17[beta]-hydroxy-
14

[5a]-androstan-3-one),
15

(xxx) methandienone (17[alpha]-methyl-17[beta]-
16

hydroxyandrost-1,4-dien-3-one),
17

(xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]-
18

dihydroxyandrost-5-ene),
19

(xxxii) methenolone (1-methyl-17[beta]-hydroxy-
20

5[alpha]-androst-1-en-3-one),
21

(xxxiii) 17[alpha]-methyl-3[beta], 17[beta]-
22

dihydroxy-5a-androstane,
23

(xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy
24

-5a-androstane,
25

(xxxv) 17[alpha]-methyl-3[beta],17[beta]-
26

dihydroxyandrost-4-ene),

SB1773 Engrossed
- 29 -
LRB104 03029 RLC 13047 b
1

(xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-
2

methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one),
3

(xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-
4

hydroxyestra-4,9(10)-dien-3-one),
5

(xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-
6

hydroxyestra-4,9-11-trien-3-one),
7

(xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-
8

hydroxyandrost-4-en-3-one),
9

(xl) mibolerone (7[alpha],17a-dimethyl-17[beta]-
10

hydroxyestr-4-en-3-one),
11

(xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone
12

(17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]-
13

androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl-
14

1-testosterone'),
15

(xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one),
16

(xliii) 19-nor-4-androstenediol (3[beta], 17[beta]-
17

dihydroxyestr-4-ene),
18

(xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]-
19

dihydroxyestr-4-ene),
20

(xlv) 19-nor-5-androstenediol (3[beta], 17[beta]-
21

dihydroxyestr-5-ene),
22

(xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]-
23

dihydroxyestr-5-ene),
24

(xlvii) 19-nor-4,9(10)-androstadienedione
25

(estra-4,9(10)-diene-3,17-dione),
26

(xlviii) 19-nor-4-androstenedione (estr-4-

SB1773 Engrossed
- 30 -
LRB104 03029 RLC 13047 b
1

en-3,17-dione),
2

(xlix) 19-nor-5-androstenedione (estr-5-
3

en-3,17-dione),
4

(l) norbolethone (13[beta], 17a-diethyl-17[beta]-
5

hydroxygon-4-en-3-one),
6

(li) norclostebol (4-chloro-17[beta]-
7

hydroxyestr-4-en-3-one),
8

(lii) norethandrolone (17[alpha]-ethyl-17[beta]-
9

hydroxyestr-4-en-3-one),
10

(liii) normethandrolone (17[alpha]-methyl-17[beta]-
11

hydroxyestr-4-en-3-one),
12

(liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-
13

2-oxa-5[alpha]-androstan-3-one),
14

(lv) oxymesterone (17[alpha]-methyl-4,17[beta]-
15

dihydroxyandrost-4-en-3-one),
16

(lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene-
17

17[beta]-hydroxy-(5[alpha]-androstan-3-one),
18

(lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy-
19

(5[alpha]-androst-2-eno[3,2-c]-pyrazole),
20

(lviii) stenbolone (17[beta]-hydroxy-2-methyl-
21

(5[alpha]-androst-1-en-3-one),
22

(lix) testolactone (13-hydroxy-3-oxo-13,17-
23

secoandrosta-1,4-dien-17-oic
24

acid lactone),
25

(lx) testosterone (17[beta]-hydroxyandrost-
26

4-en-3-one),

SB1773 Engrossed
- 31 -
LRB104 03029 RLC 13047 b
1

(lxi) tetrahydrogestrinone (13[beta], 17[alpha]-
2

diethyl-17[beta]-hydroxygon-
3

4,9,11-trien-3-one),
4

(lxii) trenbolone (17[beta]-hydroxyestr-4,9,
5

11-trien-3-one).
6

Any person who is otherwise lawfully in possession of an
7
anabolic steroid, or who otherwise lawfully manufactures,
8
distributes, dispenses, delivers, or possesses with intent to
9
deliver an anabolic steroid, which anabolic steroid is
10
expressly intended for and lawfully allowed to be administered
11
through implants to livestock or other nonhuman species, and
12
which is approved by the Secretary of Health and Human
13
Services for such administration, and which the person intends
14
to administer or have administered through such implants,
15
shall not be considered to be in unauthorized possession or to
16
unlawfully manufacture, distribute, dispense, deliver, or
17
possess with intent to deliver such anabolic steroid for
18
purposes of this Act.
19

(d) "Administration" means the Drug Enforcement
20
Administration, United States Department of Justice, or its
21
successor agency.
22

(d-5) "Clinical Director, Prescription Monitoring Program"
23
means a Department of Human Services administrative employee
24
licensed to either prescribe or dispense controlled substances
25
who shall run the clinical aspects of the Department of Human
26
Services Prescription Monitoring Program and its Prescription

SB1773 Engrossed
- 32 -
LRB104 03029 RLC 13047 b
1
Information Library.
2

(d-10) "Compounding" means the preparation and mixing of
3
components, excluding flavorings, (1) as the result of a
4
prescriber's prescription drug order or initiative based on
5
the prescriber-patient-pharmacist relationship in the course
6
of professional practice or (2) for the purpose of, or
7
incident to, research, teaching, or chemical analysis and not
8
for sale or dispensing. "Compounding" includes the preparation
9
of drugs or devices in anticipation of receiving prescription
10
drug orders based on routine, regularly observed dispensing
11
patterns. Commercially available products may be compounded
12
for dispensing to individual patients only if both of the
13
following conditions are met: (i) the commercial product is
14
not reasonably available from normal distribution channels in
15
a timely manner to meet the patient's needs and (ii) the
16
prescribing practitioner has requested that the drug be
17
compounded.
18

(e) "Control" means to add a drug or other substance, or
19
immediate precursor, to a Schedule whether by transfer from
20
another Schedule or otherwise.
21

(f) "Controlled Substance" means (i) a drug, substance,
22
immediate precursor, or synthetic drug in the Schedules of
23
Article II of this Act or (ii) a drug or other substance, or
24
immediate precursor, designated as a controlled substance by
25
the Department through administrative rule. The term does not
26
include distilled spirits, wine, malt beverages, or tobacco,

SB1773 Engrossed
- 33 -
LRB104 03029 RLC 13047 b
1
as those terms are defined or used in the Liquor Control Act of
2
1934 and the Tobacco Products Tax Act of 1995.
3

(f-5) "Controlled substance analog" means a substance:
4

(1) the chemical structure of which is substantially
5

similar to the chemical structure of a controlled
6

substance in Schedule I or II;
7

(2) which has a stimulant, depressant, or
8

hallucinogenic effect on the central nervous system that
9

is substantially similar to or greater than the stimulant,
10

depressant, or hallucinogenic effect on the central
11

nervous system of a controlled substance in Schedule I or
12

II; or
13

(3) with respect to a particular person, which such
14

person represents or intends to have a stimulant,
15

depressant, or hallucinogenic effect on the central
16

nervous system that is substantially similar to or greater
17

than the stimulant, depressant, or hallucinogenic effect
18

on the central nervous system of a controlled substance in
19

Schedule I or II.
20

(g) "Counterfeit substance" means a controlled substance,
21
which, or the container or labeling of which, without
22
authorization bears the trademark, trade name, or other
23
identifying mark, imprint, number or device, or any likeness
24
thereof, of a manufacturer, distributor, or dispenser other
25
than the person who in fact manufactured, distributed, or
26
dispensed the substance.

SB1773 Engrossed
- 34 -
LRB104 03029 RLC 13047 b
1

(h) "Deliver" or "delivery" means the actual, constructive
2
or attempted transfer of possession of a controlled substance,
3
with or without consideration, whether or not there is an
4
agency relationship. "Deliver" or "delivery" does not include
5
the donation of drugs to the extent permitted under the
6
Illinois Drug Reuse Opportunity Program Act.
7

(i) "Department" means the Illinois Department of Human
8
Services (as successor to the Department of Alcoholism and
9
Substance Abuse) or its successor agency.
10

(j) (Blank).
11

(k) "Department of Corrections" means the Department of
12
Corrections of the State of Illinois or its successor agency.
13

(l) "Department of Financial and Professional Regulation"
14
means the Department of Financial and Professional Regulation
15
of the State of Illinois or its successor agency.
16

(m) "Depressant" means any drug that (i) causes an overall
17
depression of central nervous system functions, (ii) causes
18
impaired consciousness and awareness, and (iii) can be
19
habit-forming or lead to a substance misuse or substance use
20
disorder, including, but not limited to, alcohol, cannabis and
21
its active principles and their analogs, benzodiazepines and
22
their analogs, barbiturates and their analogs, opioids
23
(natural and synthetic) and their analogs, and chloral hydrate
24
and similar sedative hypnotics.
25

(n) (Blank).
26

(o) "Director" means the Director of the Illinois State

SB1773 Engrossed
- 35 -
LRB104 03029 RLC 13047 b
1
Police or his or her designated agents.
2

(p) "Dispense" means to deliver a controlled substance to
3
an ultimate user or research subject by or pursuant to the
4
lawful order of a prescriber, including the prescribing,
5
administering, packaging, labeling, or compounding necessary
6
to prepare the substance for that delivery.
7

(q) "Dispenser" means a practitioner who dispenses.
8

(r) "Distribute" means to deliver, other than by
9
administering or dispensing, a controlled substance.
10

(s) "Distributor" means a person who distributes.
11

(t) "Drug" means (1) substances recognized as drugs in the
12
official United States Pharmacopoeia, Official Homeopathic
13
Pharmacopoeia of the United States, or official National
14
Formulary, or any supplement to any of them; (2) substances
15
intended for use in diagnosis, cure, mitigation, treatment, or
16
prevention of disease in man or animals; (3) substances (other
17
than food) intended to affect the structure of any function of
18
the body of man or animals and (4) substances intended for use
19
as a component of any article specified in clause (1), (2), or
20
(3) of this subsection. It does not include devices or their
21
components, parts, or accessories.
22

(t-3) "Electronic health record" or "EHR" means an
23
electronic record of health-related information on an
24
individual that is created, gathered, managed, and consulted
25
by authorized health care clinicians and staff.
26

(t-3.5) "Electronic health record system" or "EHR system"

SB1773 Engrossed
- 36 -
LRB104 03029 RLC 13047 b
1
means any computer-based system or combination of federally
2
certified Health IT Modules (defined at 42 CFR 170.102 or its
3
successor) used as a repository for electronic health records
4
and accessed or updated by a prescriber or authorized
5
surrogate in the ordinary course of his or her medical
6
practice. For purposes of connecting to the Prescription
7
Information Library maintained by the Bureau of Pharmacy and
8
Clinical Support Systems or its successor, an EHR system may
9
connect to the Prescription Information Library directly or
10
through all or part of a computer program or system that is a
11
federally certified Health IT Module maintained by a third
12
party and used by the EHR system to secure access to the
13
database.
14

(t-4) "Emergency medical services personnel" has the
15
meaning ascribed to it in the Emergency Medical Services (EMS)
16
Systems Act.
17

(t-5) "Euthanasia agency" means an entity certified by the
18
Department of Financial and Professional Regulation for the
19
purpose of animal euthanasia that holds an animal control
20
facility license or animal shelter license under the Animal
21
Welfare Act. A euthanasia agency is authorized to purchase,
22
store, possess, and utilize Schedule II nonnarcotic and
23
Schedule III nonnarcotic drugs for the sole purpose of animal
24
euthanasia.
25

(t-10) "Euthanasia drugs" means Schedule II or Schedule
26
III substances (nonnarcotic controlled substances) that are

SB1773 Engrossed
- 37 -
LRB104 03029 RLC 13047 b
1
used by a euthanasia agency for the purpose of animal
2
euthanasia.
3

(u) "Good faith" means the prescribing or dispensing of a
4
controlled substance by a practitioner in the regular course
5
of professional treatment to or for any person who is under his
6
or her treatment for a pathology or condition other than that
7
individual's physical or psychological dependence upon a
8
controlled substance, except as provided herein: and
9
application of the term to a pharmacist shall mean the
10
dispensing of a controlled substance pursuant to the
11
prescriber's order which in the professional judgment of the
12
pharmacist is lawful. The pharmacist shall be guided by
13
accepted professional standards, including, but not limited
14
to, the following, in making the judgment:
15

(1) lack of consistency of prescriber-patient
16

relationship,
17

(2) frequency of prescriptions for same drug by one
18

prescriber for large numbers of patients,
19

(3) quantities beyond those normally prescribed,
20

(4) unusual dosages (recognizing that there may be
21

clinical circumstances where more or less than the usual
22

dose may be used legitimately),
23

(5) unusual geographic distances between patient,
24

pharmacist and prescriber,
25

(6) consistent prescribing of habit-forming drugs.
26

(u-0.5) "Hallucinogen" means a drug that causes markedly

SB1773 Engrossed
- 38 -
LRB104 03029 RLC 13047 b
1
altered sensory perception leading to hallucinations of any
2
type.
3

(u-1) "Home infusion services" means services provided by
4
a pharmacy in compounding solutions for direct administration
5
to a patient in a private residence, long-term care facility,
6
or hospice setting by means of parenteral, intravenous,
7
intramuscular, subcutaneous, or intraspinal infusion.
8

(u-5) "Illinois State Police" means the Illinois State
9
Police or its successor agency.
10

(v) "Immediate precursor" means a substance:
11

(1) which the Department has found to be and by rule
12

designated as being a principal compound used, or produced
13

primarily for use, in the manufacture of a controlled
14

substance;
15

(2) which is an immediate chemical intermediary used
16

or likely to be used in the manufacture of such controlled
17

substance; and
18

(3) the control of which is necessary to prevent,
19

curtail or limit the manufacture of such controlled
20

substance.
21

(w) "Instructional activities" means the acts of teaching,
22
educating or instructing by practitioners using controlled
23
substances within educational facilities approved by the State
24
Board of Education or its successor agency.
25

(w-1) "Isomer" means optical isomer, unless specifically
26
detailed in this Act.

SB1773 Engrossed
- 39 -
LRB104 03029 RLC 13047 b
1

(x) "Local authorities" means a duly organized State,
2
County or Municipal peace unit or police force.
3

(y) "Look-alike substance" means a substance, other than a
4
controlled substance which (1) by overall dosage unit
5
appearance, including shape, color, size, markings or lack
6
thereof, taste, consistency, or any other identifying physical
7
characteristic of the substance, would lead a reasonable
8
person to believe that the substance is a controlled
9
substance, or (2) is expressly or impliedly represented to be
10
a controlled substance or is distributed under circumstances
11
which would lead a reasonable person to believe that the
12
substance is a controlled substance. For the purpose of
13
determining whether the representations made or the
14
circumstances of the distribution would lead a reasonable
15
person to believe the substance to be a controlled substance
16
under this clause (2) of subsection (y), the court or other
17
authority may consider the following factors in addition to
18
any other factor that may be relevant:
19

(a) statements made by the owner or person in control
20

of the substance concerning its nature, use or effect;
21

(b) statements made to the buyer or recipient that the
22

substance may be resold for profit;
23

(c) whether the substance is packaged in a manner
24

normally used for the illegal distribution of controlled
25

substances;
26

(d) whether the distribution or attempted distribution

SB1773 Engrossed
- 40 -
LRB104 03029 RLC 13047 b
1

included an exchange of or demand for money or other
2

property as consideration, and whether the amount of the
3

consideration was substantially greater than the
4

reasonable retail market value of the substance.
5

Clause (1) of this subsection (y) shall not apply to a
6
noncontrolled substance in its finished dosage form that was
7
initially introduced into commerce prior to the initial
8
introduction into commerce of a controlled substance in its
9
finished dosage form which it may substantially resemble.
10

Nothing in this subsection (y) prohibits the dispensing or
11
distributing of noncontrolled substances by persons authorized
12
to dispense and distribute controlled substances under this
13
Act, provided that such action would be deemed to be carried
14
out in good faith under subsection (u) if the substances
15
involved were controlled substances.
16

Nothing in this subsection (y) or in this Act prohibits
17
the manufacture, preparation, propagation, compounding,
18
processing, packaging, advertising or distribution of a drug
19
or drugs by any person registered pursuant to Section 510 of
20
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
21

(y-1) "Mail-order pharmacy" means a pharmacy that is
22
located in a state of the United States that delivers,
23
dispenses or distributes, through the United States Postal
24
Service or other common carrier, to Illinois residents, any
25
substance which requires a prescription.
26

(z) "Manufacture" means the production, preparation,

SB1773 Engrossed
- 41 -
LRB104 03029 RLC 13047 b
1
propagation, compounding, conversion or processing of a
2
controlled substance other than methamphetamine, either
3
directly or indirectly, by extraction from substances of
4
natural origin, or independently by means of chemical
5
synthesis, or by a combination of extraction and chemical
6
synthesis, and includes any packaging or repackaging of the
7
substance or labeling of its container, except that this term
8
does not include:
9

(1) by an ultimate user, the preparation or
10

compounding of a controlled substance for his or her own
11

use;
12

(2) by a practitioner, or his or her authorized agent
13

under his or her supervision, the preparation,
14

compounding, packaging, or labeling of a controlled
15

substance:
16

(a) as an incident to his or her administering or
17

dispensing of a controlled substance in the course of
18

his or her professional practice; or
19

(b) as an incident to lawful research, teaching or
20

chemical analysis and not for sale; or
21

(3) the packaging, repackaging, or labeling of drugs
22

only to the extent permitted under the Illinois Drug Reuse
23

Opportunity Program Act.
24

(z-1) (Blank).
25

(z-5) "Medication shopping" means the conduct prohibited
26
under subsection (a) of Section 314.5 of this Act.

SB1773 Engrossed
- 42 -
LRB104 03029 RLC 13047 b
1

(z-10) "Mid-level practitioner" means (i) a physician
2
assistant who has been delegated authority to prescribe
3
through a written delegation of authority by a physician
4
licensed to practice medicine in all of its branches, in
5
accordance with Section 7.5 of the Physician Assistant
6
Practice Act of 1987, (ii) an advanced practice registered
7
nurse who has been delegated authority to prescribe through a
8
written delegation of authority by a physician licensed to
9
practice medicine in all of its branches or by a podiatric
10
physician, in accordance with Section 65-40 of the Nurse
11
Practice Act, (iii) an advanced practice registered nurse
12
certified as a nurse practitioner, nurse midwife, or clinical
13
nurse specialist who has been granted authority to prescribe
14
by a hospital affiliate in accordance with Section 65-45 of
15
the Nurse Practice Act, (iv) an animal euthanasia agency, or
16
(v) a prescribing psychologist.
17

(aa) "Narcotic drug" means any of the following, whether
18
produced directly or indirectly by extraction from substances
19
of vegetable origin, or independently by means of chemical
20
synthesis, or by a combination of extraction and chemical
21
synthesis:
22

(1) opium, opiates, derivatives of opium and opiates,
23

including their isomers, esters, ethers, salts, and salts
24

of isomers, esters, and ethers, whenever the existence of
25

such isomers, esters, ethers, and salts is possible within
26

the specific chemical designation; however the term

SB1773 Engrossed
- 43 -
LRB104 03029 RLC 13047 b
1

"narcotic drug" does not include the isoquinoline
2

alkaloids of opium;
3

(2) (blank);
4

(3) opium poppy and poppy straw;
5

(4) coca leaves, except coca leaves and extracts of
6

coca leaves from which substantially all of the cocaine
7

and ecgonine, and their isomers, derivatives and salts,
8

have been removed;
9

(5) cocaine, its salts, optical and geometric isomers,
10

and salts of isomers;
11

(6) ecgonine, its derivatives, their salts, isomers,
12

and salts of isomers;
13

(7) any compound, mixture, or preparation which
14

contains any quantity of any of the substances referred to
15

in subparagraphs (1) through (6).
16

(bb) "Nurse" means a registered nurse licensed under the
17
Nurse Practice Act.
18

(cc) (Blank).
19

(dd) "Opiate" means a drug derived from or related to
20
opium.
21

(ee) "Opium poppy" means the plant of the species Papaver
22
somniferum L., except its seeds.
23

(ee-5) "Oral dosage" means a tablet, capsule, elixir, or
24
solution or other liquid form of medication intended for
25
administration by mouth, but the term does not include a form
26
of medication intended for buccal, sublingual, or transmucosal

SB1773 Engrossed
- 44 -
LRB104 03029 RLC 13047 b
1
administration.
2

(ff) "Parole and Pardon Board" means the Parole and Pardon
3
Board of the State of Illinois or its successor agency.
4

(gg) "Person" means any individual, corporation,
5
mail-order pharmacy, government or governmental subdivision or
6
agency, business trust, estate, trust, partnership or
7
association, or any other entity.
8

(hh) "Pharmacist" means any person who holds a license or
9
certificate of registration as a registered pharmacist, a
10
local registered pharmacist or a registered assistant
11
pharmacist under the Pharmacy Practice Act.
12

(ii) "Pharmacy" means any store, ship or other place in
13
which pharmacy is authorized to be practiced under the
14
Pharmacy Practice Act.
15

(ii-5) "Pharmacy shopping" means the conduct prohibited
16
under subsection (b) of Section 314.5 of this Act.
17

(ii-10) "Physician" (except when the context otherwise
18
requires) means a person licensed to practice medicine in all
19
of its branches.
20

(jj) "Poppy straw" means all parts, except the seeds, of
21
the opium poppy, after mowing.
22

(kk) "Practitioner" means a physician licensed to practice
23
medicine in all its branches, dentist, optometrist, podiatric
24
physician, veterinarian, scientific investigator, pharmacist,
25
physician assistant, advanced practice registered nurse,
26
licensed practical nurse, registered nurse, emergency medical

SB1773 Engrossed
- 45 -
LRB104 03029 RLC 13047 b
1
services personnel, hospital, laboratory, or pharmacy, or
2
other person licensed, registered, or otherwise lawfully
3
permitted by the United States or this State to distribute,
4
dispense, conduct research with respect to, administer or use
5
in teaching or chemical analysis, a controlled substance in
6
the course of professional practice or research.
7

(ll) "Pre-printed prescription" means a written
8
prescription upon which the designated drug has been indicated
9
prior to the time of issuance; the term does not mean a written
10
prescription that is individually generated by machine or
11
computer in the prescriber's office.
12

(mm) "Prescriber" means a physician licensed to practice
13
medicine in all its branches, dentist, optometrist,
14
prescribing psychologist licensed under Section 4.2 of the
15
Clinical Psychologist Licensing Act with prescriptive
16
authority delegated under Section 4.3 of the Clinical
17
Psychologist Licensing Act, podiatric physician, or
18
veterinarian who issues a prescription, a physician assistant
19
who issues a prescription for a controlled substance in
20
accordance with Section 303.05, a written delegation, and a
21
written collaborative agreement required under Section 7.5 of
22
the Physician Assistant Practice Act of 1987, an advanced
23
practice registered nurse with prescriptive authority
24
delegated under Section 65-40 of the Nurse Practice Act and in
25
accordance with Section 303.05, a written delegation, and a
26
written collaborative agreement under Section 65-35 of the

SB1773 Engrossed
- 46 -
LRB104 03029 RLC 13047 b
1
Nurse Practice Act, an advanced practice registered nurse
2
certified as a nurse practitioner, nurse midwife, or clinical
3
nurse specialist who has been granted authority to prescribe
4
by a hospital affiliate in accordance with Section 65-45 of
5
the Nurse Practice Act and in accordance with Section 303.05,
6
or an advanced practice registered nurse certified as a nurse
7
practitioner, nurse midwife, or clinical nurse specialist who
8
has full practice authority pursuant to Section 65-43 of the
9
Nurse Practice Act.
10

(nn) "Prescription" means a written, facsimile, or oral
11
order, or an electronic order that complies with applicable
12
federal requirements, of a physician licensed to practice
13
medicine in all its branches, dentist, podiatric physician or
14
veterinarian for any controlled substance, of an optometrist
15
in accordance with Section 15.1 of the Illinois Optometric
16
Practice Act of 1987, of a prescribing psychologist licensed
17
under Section 4.2 of the Clinical Psychologist Licensing Act
18
with prescriptive authority delegated under Section 4.3 of the
19
Clinical Psychologist Licensing Act, of a physician assistant
20
for a controlled substance in accordance with Section 303.05,
21
a written delegation, and a written collaborative agreement
22
required under Section 7.5 of the Physician Assistant Practice
23
Act of 1987, of an advanced practice registered nurse with
24
prescriptive authority delegated under Section 65-40 of the
25
Nurse Practice Act who issues a prescription for a controlled
26
substance in accordance with Section 303.05, a written

SB1773 Engrossed
- 47 -
LRB104 03029 RLC 13047 b
1
delegation, and a written collaborative agreement under
2
Section 65-35 of the Nurse Practice Act, of an advanced
3
practice registered nurse certified as a nurse practitioner,
4
nurse midwife, or clinical nurse specialist who has been
5
granted authority to prescribe by a hospital affiliate in
6
accordance with Section 65-45 of the Nurse Practice Act and in
7
accordance with Section 303.05 when required by law, or of an
8
advanced practice registered nurse certified as a nurse
9
practitioner, nurse midwife, or clinical nurse specialist who
10
has full practice authority pursuant to Section 65-43 of the
11
Nurse Practice Act.
12

(nn-5) "Prescription Information Library" (PIL) means an
13
electronic library that contains reported controlled substance
14
data.
15

(nn-10) "Prescription Monitoring Program" (PMP) means the
16
entity that collects, tracks, and stores reported data on
17
controlled substances and select drugs pursuant to Section
18
316.
19

(oo) "Production" or "produce" means manufacture,
20
planting, cultivating, growing, or harvesting of a controlled
21
substance other than methamphetamine.
22

(pp) "Registrant" means every person who is required to
23
register under Section 302 of this Act.
24

(qq) "Registry number" means the number assigned to each
25
person authorized to handle controlled substances under the
26
laws of the United States and of this State.

SB1773 Engrossed
- 48 -
LRB104 03029 RLC 13047 b
1

(qq-5) "Secretary" means, as the context requires, either
2
the Secretary of the Department or the Secretary of the
3
Department of Financial and Professional Regulation, and the
4
Secretary's designated agents.
5

(rr) "State" includes the State of Illinois and any state,
6
district, commonwealth, territory, insular possession thereof,
7
and any area subject to the legal authority of the United
8
States of America.
9

(rr-5) "Stimulant" means any drug that (i) causes an
10
overall excitation of central nervous system functions, (ii)
11
causes impaired consciousness and awareness, and (iii) can be
12
habit-forming or lead to a substance use disorder, including,
13
but not limited to, amphetamines and their analogs,
14
methylphenidate and its analogs, cocaine, and phencyclidine
15
and its analogs.
16

(rr-10) "Synthetic drug" includes, but is not limited to,
17
any synthetic cannabinoids or piperazines or any synthetic
18
cathinones as provided for in Schedule I.
19

(ss) "Ultimate user" means a person who lawfully possesses
20
a controlled substance for his or her own use or for the use of
21
a member of his or her household or for administering to an
22
animal owned by him or her or by a member of his or her
23
household.
24
(Source: P.A. 102-389, eff. 1-1-22; 102-538, eff. 8-20-21;
25
102-813, eff. 5-13-22; 103-881, eff. 1-1-25.)

SB1773 Engrossed
- 49 -
LRB104 03029 RLC 13047 b
1

(720 ILCS 570/204)

(from Ch. 56 1/2, par. 1204)
2

Sec. 204.
(a) The controlled substances listed in this
3
Section are included in Schedule I.
4

(b) Unless specifically excepted or unless listed in
5
another schedule, any of the following opiates, including
6
their isomers, esters, ethers, salts, and salts of isomers,
7
esters, and ethers, whenever the existence of such isomers,
8
esters, ethers and salts is possible within the specific
9
chemical designation:
10

(1) Acetylmethadol;
11

(1.1)
(Blank);

Acetyl-alpha-methylfentanyl
12

(N-[1-(1-methyl-2-phenethyl)-

13

4-piperidinyl]-N-phenylacetamide);
14

(2) Allylprodine;
15

(3) Alphacetylmethadol, except

16

levo-alphacetylmethadol (also known as levo-alpha-

17

acetylmethadol, levomethadyl acetate, or LAAM);
18

(4) Alphameprodine;
19

(5) Alphamethadol;
20

(6) Alpha-methylfentanyl

21

(N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)

22

propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-

23

propanilido) piperidine;
24

(6.1)
(Blank);

Alpha-methylthiofentanyl

25

(N-[1-methyl-2-(2-thienyl)ethyl-

26

4-piperidinyl]-N-phenylpropanamide);

SB1773 Engrossed
- 50 -
LRB104 03029 RLC 13047 b
1

(7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
2

(7.1) PEPAP

3

(1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
4

(8) Benzethidine;
5

(9) Betacetylmethadol;
6

(9.1)
(Blank);

Beta-hydroxyfentanyl

7

(N-[1-(2-hydroxy-2-phenethyl)-

8

4-piperidinyl]-N-phenylpropanamide);
9

(10) Betameprodine;
10

(11) Betamethadol;
11

(12) Betaprodine;
12

(12.1) Brorphine;

13

(13) Clonitazene;
14

(14) Dextromoramide;
15

(15) Diampromide;
16

(16) Diethylthiambutene;
17

(17) Difenoxin;
18

(18) Dimenoxadol;
19

(19) Dimepheptanol;
20

(20) Dimethylthiambutene;
21

(21) Dioxaphetylbutyrate;
22

(22) Dipipanone;
23

(23) Ethylmethylthiambutene;
24

(24) Etonitazene;
25

(25) Etoxeridine;
26

(25.1) Flunitazene;

SB1773 Engrossed
- 51 -
LRB104 03029 RLC 13047 b
1

(26) Furethidine;
2

(27) Hydroxpethidine;
3

(27.1) Isotonitazene;

4

(28) Ketobemidone;
5

(29) Levomoramide;
6

(30) Levophenacylmorphan;
7

(31)
(Blank);

3-Methylfentanyl

8

(N-[3-methyl-1-(2-phenylethyl)-

9

4-piperidyl]-N-phenylpropanamide);
10

(31.1)
(Blank);

3-Methylthiofentanyl

11

(N-[(3-methyl-1-(2-thienyl)ethyl-

12

4-piperidinyl]-N-phenylpropanamide);
13

(31.2) Metonitazene;

14

(32) Morpheridine;
15

(33) Noracymethadol;
16

(34) Norlevorphanol;
17

(35) Normethadone;
18

(36) Norpipanone;
19

(36.1)
(Blank);

Para-fluorofentanyl

20

(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-

21

4-piperidinyl]propanamide);
22

(37) Phenadoxone;
23

(38) Phenampromide;
24

(39) Phenomorphan;
25

(40) Phenoperidine;
26

(41) Piritramide;

SB1773 Engrossed
- 52 -
LRB104 03029 RLC 13047 b
1

(42) Proheptazine;
2

(43) Properidine;
3

(44) Propiram;
4

(45) Racemoramide;
5

(45.1)
(Blank);

Thiofentanyl

6

(N-phenyl-N-[1-(2-thienyl)ethyl-

7

4-piperidinyl]-propanamide);
8

(46) Tilidine;
9

(47) Trimeperidine;
10

(48)
(Blank);

Beta-hydroxy-3-methylfentanyl (other
11
name:

12

N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-

13

N-phenylpropanamide);
14

(49)
(Blank);

Furanyl fentanyl (FU-F);
15

(50)
(Blank);

Butyryl fentanyl;
16

(51)
(Blank);

Valeryl fentanyl;
17

(52)
(Blank);

Acetyl fentanyl;
18

(53)
(Blank);

Beta-hydroxy-thiofentanyl;

19

(54) 3,4-dichloro-N-[2-

20

(dimethylamino)cyclohexyl]-N-

21

methylbenzamide (U-47700);
22

(55) 4-chloro-N-[1-[2-

23

(4-nitrophenyl)ethyl]-2-piperidinylidene]-

24

benzenesulfonamide (W-18);
25

(56) 4-chloro-N-[1-(2-phenylethyl)

26

-2-piperidinylidene]-benzenesulfonamide (W-15);

SB1773 Engrossed
- 53 -
LRB104 03029 RLC 13047 b
1

(57)
(Blank).

acrylfentanyl (acryloylfentanyl).

2

(c) Unless specifically excepted or unless listed in
3
another schedule, any of the following opium derivatives, its
4
salts, isomers and salts of isomers, whenever the existence of
5
such salts, isomers and salts of isomers is possible within
6
the specific chemical designation:
7

(1) Acetorphine;
8

(2) Acetyldihydrocodeine;
9

(3) Benzylmorphine;
10

(4) Codeine methylbromide;
11

(5) Codeine-N-Oxide;
12

(6) Cyprenorphine;
13

(7) Desomorphine;
14

(8) Diacetyldihydromorphine (Dihydroheroin);
15

(9) Dihydromorphine;
16

(10) Drotebanol;
17

(11) Etorphine (except hydrochloride salt);
18

(12) Heroin;
19

(13) Hydromorphinol;
20

(14) Methyldesorphine;
21

(15) Methyldihydromorphine;
22

(16) Morphine methylbromide;
23

(17) Morphine methylsulfonate;
24

(18) Morphine-N-Oxide;
25

(19) Myrophine;
26

(20) Nicocodeine;

SB1773 Engrossed
- 54 -
LRB104 03029 RLC 13047 b
1

(21) Nicomorphine;
2

(22) Normorphine;
3

(23) Pholcodine;
4

(24) Thebacon.
5

(d) Unless specifically excepted or unless listed in
6
another schedule, any material, compound, mixture, or
7
preparation which contains any quantity of the following
8
hallucinogenic substances, or which contains any of its salts,
9
isomers and salts of isomers, whenever the existence of such
10
salts, isomers, and salts of isomers is possible within the
11
specific chemical designation (for the purposes of this
12
paragraph only, the term "isomer" includes the optical,
13
position and geometric isomers):
14

(1) 3,4-methylenedioxyamphetamine

15
(alpha-methyl,3,4-methylenedioxyphenethylamine,

16
methylenedioxyamphetamine, MDA);
17

(1.1) Alpha-ethyltryptamine
18

(some trade or other names: etryptamine;
19

MONASE; alpha-ethyl-1H-indole-3-ethanamine;
20

3-(2-aminobutyl)indole; a-ET; and AET);
21

(2) 3,4-methylenedioxymethamphetamine (MDMA);
22

(2.1) 3,4-methylenedioxy-N-ethylamphetamine

23
(also known as: N-ethyl-alpha-methyl-

24
3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,

25
and MDEA);
26

(2.2)
(Blank);

N-Benzylpiperazine (BZP);

SB1773 Engrossed
- 55 -
LRB104 03029 RLC 13047 b
1

(2.2-1)
(Blank);

Trifluoromethylphenylpiperazine
2

(TFMPP);

3

(3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
4

(4) 3,4,5-trimethoxyamphetamine (TMA);
5

(5) (Blank);
6

(6) Diethyltryptamine (DET);
7

(7) Dimethyltryptamine (DMT);
8

(7.1) 5-Methoxy-diallyltryptamine;
9

(8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
10

(9) Ibogaine (some trade and other names:

11

7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-

12

6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]

13

indole; Tabernanthe iboga);
14

(10) Lysergic acid diethylamide;
15

(10.1) Salvinorin A;
16

(10.5) Salvia divinorum (meaning all parts of the
17

plant presently classified botanically as Salvia
18

divinorum, whether growing or not, the seeds thereof, any
19

extract from any part of that plant, and every compound,
20

manufacture, salts, isomers, and salts of isomers whenever
21

the existence of such salts, isomers, and salts of isomers
22

is possible within the specific chemical designation,
23

derivative, mixture, or preparation of that plant, its
24

seeds or extracts);
25

(11) 3,4,5-trimethoxyphenethylamine (Mescaline);
26

(12) Peyote (meaning all parts of the plant presently

SB1773 Engrossed
- 56 -
LRB104 03029 RLC 13047 b
1

classified botanically as Lophophora williamsii Lemaire,
2

whether growing or not, the seeds thereof, any extract
3

from any part of that plant, and every compound,
4

manufacture, salts, derivative, mixture, or preparation of
5

that plant, its seeds or extracts);
6

(13) N-ethyl-3-piperidyl benzilate (JB 318);
7

(14) N-methyl-3-piperidyl benzilate;
8

(14.1) N-hydroxy-3,4-methylenedioxyamphetamine

9

(also known as N-hydroxy-alpha-methyl-

10

3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
11

(15) Parahexyl; some trade or other names:

12
3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-

13
dibenzo (b,d) pyran; Synhexyl;
14

(16) Psilocybin;
15

(17) Psilocyn;
16

(18) Alpha-methyltryptamine (AMT);
17

(19) 2,5-dimethoxyamphetamine

18

(2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
19

(20) 4-bromo-2,5-dimethoxyamphetamine

20

(4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;

21

4-bromo-2,5-DMA);
22

(20.1) 4-Bromo-2,5 dimethoxyphenethylamine.

23
Some trade or other names: 2-(4-bromo-

24
2,5-dimethoxyphenyl)-1-aminoethane;

25
alpha-desmethyl DOB, 2CB, Nexus;
26

(21) 4-methoxyamphetamine

SB1773 Engrossed
- 57 -
LRB104 03029 RLC 13047 b
1

(4-methoxy-alpha-methylphenethylamine;

2

paramethoxyamphetamine; PMA);
3

(22) (Blank);
4

(23) Ethylamine analog of phencyclidine.

5
Some trade or other names:

6
N-ethyl-1-phenylcyclohexylamine,

7
(1-phenylcyclohexyl) ethylamine,

8
N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
9

(24) Pyrrolidine analog of phencyclidine. Some trade
10

or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
11

PHP;
12

(25) 5-methoxy-3,4-methylenedioxy-amphetamine;
13

(26) 2,5-dimethoxy-4-ethylamphetamine

14

(another name: DOET);
15

(27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine

16

(another name: TCPy);
17

(28) (Blank);
18

(29) Thiophene analog of phencyclidine (some trade

19
or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;

20
2-thienyl analog of phencyclidine; TPCP; TCP);
21

(29.1) Benzothiophene analog of phencyclidine. Some
22

trade or other names: BTCP or benocyclidine;
23

(29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
24

(30) Bufotenine (some trade or other names:

25

3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;

26

3-(2-dimethylaminoethyl)-5-indolol;

SB1773 Engrossed
- 58 -
LRB104 03029 RLC 13047 b
1

5-hydroxy-N,N-dimethyltryptamine;

2

N,N-dimethylserotonin; mappine);
3

(31) (Blank);
4

(32) (Blank);
5

(33) (Blank);
6

(34) (Blank);
7

(34.5) (Blank);
8

(35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
9

(2-methyloctan-2-yl)-6a,7,
10

10,10a-tetrahydrobenzo[c]chromen-1-ol
11

Some trade or other names: HU-210;
12

(35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-
13

dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
14

tetrahydrobenzo[c]chromen-1-ol, its isomers,
15

salts, and salts of isomers; Some trade or other
16

names: HU-210, Dexanabinol;
17

(36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
18

6,6-dimethyl-3-(2-methyloctan-2-yl)-
19

6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
20

Some trade or other names: HU-211;
21

(37) (Blank);
22

(38) (Blank);
23

(39) (Blank);
24

(40) (Blank);
25

(41) (Blank);
26

(42)
(Blank);

Any compound structurally derived from

SB1773 Engrossed
- 59 -
LRB104 03029 RLC 13047 b
1

3-(1-naphthoyl)indole or
2

1H-indol-3-yl-(1-naphthyl)methane by substitution at the
3

nitrogen atom of the indole ring by alkyl, haloalkyl,
4

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
5

alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
6

2-(4-morpholinyl)ethyl whether or not further substituted
7

in the indole ring to any extent, whether or not
8

substituted in the naphthyl ring to any extent. Examples
9

of this structural class include, but are not limited to,
10

JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;
11

(43)
(Blank);

Any compound structurally derived from
12

3-(1-naphthoyl)pyrrole by substitution at the nitrogen
13

atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
14

cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
15

halide, 1-(N-methyl-2-piperidinyl)methyl, or
16

2-(4-morpholinyl)ethyl, whether or not further substituted
17

in the pyrrole ring to any extent, whether or not
18

substituted in the naphthyl ring to any extent. Examples
19

of this structural class include, but are not limited to,
20

JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;

21

(44)
(Blank);

Any compound structurally derived from
22

1-(1-naphthylmethyl)indene by substitution at the
23

3-position of the indene ring by alkyl, haloalkyl,
24

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
25

alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
26

2-(4-morpholinyl)ethyl whether or not further substituted

SB1773 Engrossed
- 60 -
LRB104 03029 RLC 13047 b
1

in the indene ring to any extent, whether or not
2

substituted in the naphthyl ring to any extent. Examples
3

of this structural class include, but are not limited to,
4

JWH-176;

5

(45)
(Blank);

Any compound structurally derived from
6

3-phenylacetylindole by substitution at the nitrogen atom
7

of the indole ring with alkyl, haloalkyl, alkenyl,
8

cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
9

halide, 1-(N-methyl-2-piperidinyl)methyl, or
10

2-(4-morpholinyl)ethyl, whether or not further substituted
11

in the indole ring to any extent, whether or not
12

substituted in the phenyl ring to any extent. Examples of
13

this structural class include, but are not limited to,
14

JWH-167, JWH-250, JWH-251, and RCS-8;

15

(46)
(Blank);

Any compound structurally derived from
16

2-(3-hydroxycyclohexyl)phenol by substitution at the
17

5-position of the phenolic ring by alkyl, haloalkyl,
18

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
19

alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
20

2-(4-morpholinyl)ethyl, whether or not substituted in the
21

cyclohexyl ring to any extent. Examples of this structural
22

class include, but are not limited to, CP 47, 497 and its
23

C8 homologue (cannabicyclohexanol);

24

(46.1)
(Blank);

Any compound structurally derived from
25

3-(benzoyl) indole with substitution at the nitrogen atom
26

of the indole ring by an alkyl, haloalkyl, alkenyl,

SB1773 Engrossed
- 61 -
LRB104 03029 RLC 13047 b
1

cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
2

halide, 1-(N-methyl-2-piperidinyl)methyl, or
3

2-(4-morpholinyl)ethyl group whether or not further
4

substituted in the indole ring to any extent and whether
5

or not substituted in the phenyl ring to any extent.
6

Examples of this structural class include, but are not
7

limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN
8

48,098), and RCS-4;

9

(47) (Blank);
10

(48) (Blank);
11

(49) (Blank);
12

(50) (Blank);
13

(51) (Blank);
14

(52) (Blank);
15

(53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.
16

Some trade or other names: 2C-T-7;
17

(53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some
18

trade or other names: 2C-E;
19

(53.2) 2,5-dimethoxy-4-methylphenethylamine. Some
20

trade or other names: 2C-D;
21

(53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some
22

trade or other names: 2C-C;
23

(53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade
24

or other names: 2C-I;
25

(53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some
26

trade or other names: 2C-T-2;

SB1773 Engrossed
- 62 -
LRB104 03029 RLC 13047 b
1

(53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.
2

Some trade or other names: 2C-T-4;
3

(53.7) 2,5-dimethoxyphenethylamine. Some trade or
4

other names: 2C-H;
5

(53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some
6

trade or other names: 2C-N;
7

(53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some
8

trade or other names: 2C-P;
9

(53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine.
10

Some trade or other names: 2C-G;
11

(53.11) The N-(2-methoxybenzyl) derivative of any 2C
12

phenethylamine referred to in subparagraphs (20.1), (53),
13

(53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
14

(53.8), (53.9), and (53.10) including, but not limited to,
15

25I-NBOMe and 25C-NBOMe;
16

(54) 5-Methoxy-N,N-diisopropyltryptamine;
17

(55) (Blank);
18

(56) (Blank);
19

(57) (Blank);
20

(58) (Blank);
21

(59)
(Blank);

3-cyclopropoylindole with substitution
22

at the nitrogen atom of the indole ring by alkyl,
23

haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
24

aryl halide, alkyl aryl halide,
25

1-(N-methyl-2-piperidinyl)methyl, or
26

2-(4-morpholinyl)ethyl, whether or not further substituted

SB1773 Engrossed
- 63 -
LRB104 03029 RLC 13047 b
1

on the indole ring to any extent, whether or not
2

substituted on the cyclopropyl ring to any extent:
3

including, but not limited to, XLR11, UR144, FUB-144;

4

(60)
(Blank);

3-adamantoylindole with substitution at
5

the nitrogen atom of the indole ring by alkyl, haloalkyl,
6

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
7

alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
8

2-(4-morpholinyl)ethyl, whether or not further substituted
9

on the indole ring to any extent, whether or not
10

substituted on the adamantyl ring to any extent:
11

including, but not limited to, AB-001;

12

(61)
(Blank);

N-(adamantyl)-indole-3-carboxamide with
13

substitution at the nitrogen atom of the indole ring by
14

alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
15

cycloalkylethyl, aryl halide, alkyl aryl halide,
16

1-(N-methyl-2-piperidinyl)methyl, or
17

2-(4-morpholinyl)ethyl, whether or not further substituted
18

on the indole ring to any extent, whether or not
19

substituted on the adamantyl ring to any extent:
20

including, but not limited to, APICA/2NE-1, STS-135;

21

(62)
(Blank);

N-(adamantyl)-indazole-3-carboxamide
22

with substitution at a nitrogen atom of the indazole ring
23

by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
24

cycloalkylethyl, aryl halide, alkyl aryl halide,
25

1-(N-methyl-2-piperidinyl)methyl, or
26

2-(4-morpholinyl)ethyl, whether or not further substituted

SB1773 Engrossed
- 64 -
LRB104 03029 RLC 13047 b
1

on the indazole ring to any extent, whether or not
2

substituted on the adamantyl ring to any extent:
3

including, but not limited to, AKB48, 5F-AKB48;

4

(63)
(Blank);

1H-indole-3-carboxylic acid
5

8-quinolinyl ester with substitution at the nitrogen atom
6

of the indole ring by alkyl, haloalkyl, alkenyl,
7

cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
8

halide, 1-(N-methyl-2-piperidinyl)methyl, or
9

2-(4-morpholinyl)ethyl, whether or not further substituted
10

on the indole ring to any extent, whether or not
11

substituted on the quinoline ring to any extent:
12

including, but not limited to, PB22, 5F-PB22, FUB-PB-22;

13

(64)
(Blank);

3-(1-naphthoyl)indazole with
14

substitution at the nitrogen atom of the indazole ring by
15

alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
16

cycloalkylethyl, aryl halide, alkyl aryl halide,
17

1-(N-methyl-2-piperidinyl)methyl, or
18

2-(4-morpholinyl)ethyl, whether or not further substituted
19

on the indazole ring to any extent, whether or not
20

substituted on the naphthyl ring to any extent: including,
21

but not limited to, THJ-018, THJ-2201;

22

(65)
(Blank);

2-(1-naphthoyl)benzimidazole with
23

substitution at the nitrogen atom of the benzimidazole
24

ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
25

cycloalkylethyl, aryl halide, alkyl aryl halide,
26

1-(N-methyl-2-piperidinyl)methyl, or

SB1773 Engrossed
- 65 -
LRB104 03029 RLC 13047 b
1

2-(4-morpholinyl)ethyl, whether or not further substituted
2

on the benzimidazole ring to any extent, whether or not
3

substituted on the naphthyl ring to any extent: including,
4

but not limited to, FUBIMINA;

5

(66)
(Blank);

N-(1-amino-3-methyl-1-oxobutan-2-yl)-
6

1H-indazole-3-carboxamide with substitution on the
7

nitrogen atom of the indazole ring by alkyl, haloalkyl,
8

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
9

alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
10

2-(4-morpholinyl)ethyl, whether or not further substituted
11

on the indazole ring to any extent: including, but not
12

limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;

13

(67)
(Blank);

N-(1-amino-3,3-dimethyl-1-oxobutan-
14

2-yl)-1H-indazole-3-carboxamide with substitution on the
15

nitrogen atom of the indazole ring by alkyl, haloalkyl,
16

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
17

alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
18

2-(4-morpholinyl)ethyl, whether or not further substituted
19

on the indazole ring to any extent: including, but not
20

limited to, ADB-PINACA, ADB-FUBINACA;

21

(68)
(Blank);

N-(1-amino-3,3-dimethyl-1-oxobutan-
22

2-yl)-1H-indole-3-carboxamide with substitution on the
23

nitrogen atom of the indole ring by alkyl, haloalkyl,
24

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
25

alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
26

2-(4-morpholinyl)ethyl, whether or not further substituted

SB1773 Engrossed
- 66 -
LRB104 03029 RLC 13047 b
1

on the indole ring to any extent: including, but not
2

limited to, ADBICA, 5F-ADBICA;

3

(69)
(Blank);

N-(1-amino-3-methyl-1-oxobutan-2 -
4

yl)-1H-indole-3-carboxamide with substitution on the
5

nitrogen atom of the indole ring by alkyl, haloalkyl,
6

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
7

alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
8

2-(4-morpholinyl)ethyl, whether or not further substituted
9

on the indole ring to any extent: including, but not
10

limited to, ABICA, 5F-ABICA;

11

(70)
(Blank);

Methyl 2-(1H-indazole-3-carboxamido)-3-
12

methylbutanoate with substitution on the nitrogen atom of
13

the indazole ring by alkyl, haloalkyl, alkenyl,
14

cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
15

halide, 1-(N-methyl-2-piperidinyl)methyl, or
16

2-(4-morpholinyl)ethyl, whether or not further substituted
17

on the indazole ring to any extent: including, but not
18

limited to, AMB, 5F-AMB;

19

(71)
(Blank);

Methyl 2-(1H-indazole-3-carboxamido)-
20

3,3-dimethylbutanoate with substitution on the nitrogen
21

atom of the indazole ring by alkyl, haloalkyl, alkenyl,
22

cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
23

halide, 1-(N-methyl-2-piperidinyl)methyl, or
24

2-(4-morpholinyl)ethyl, whether or not further substituted
25

on the indazole ring to any extent: including, but not
26

limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;

SB1773 Engrossed
- 67 -
LRB104 03029 RLC 13047 b
1

(72)
(Blank);

Methyl 2-(1H-indole-3-carboxamido)-3-
2

methylbutanoate with substitution on the nitrogen atom of
3

the indole ring by alkyl, haloalkyl, alkenyl,
4

cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
5

halide, 1-(N-methyl-2-piperidinyl)methyl, or
6

2-(4-morpholinyl)ethyl, whether or not further substituted
7

on the indazole ring to any extent: including, but not
8

limited to, MMB018, MMB2201, and AMB-CHMICA;

9

(73)
(Blank);

Methyl 2-(1H-indole-3-carboxamido)-3,3-
10

dimethylbutanoate with substitution on the nitrogen atom
11

of the indole ring by alkyl, haloalkyl, alkenyl,
12

cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
13

halide, 1-(N-methyl-2-piperidinyl)methyl, or
14

2-(4-morpholinyl)ethyl, whether or not further substituted
15

on the indazole ring to any extent: including, but not
16

limited to, MDMB-CHMICA;

17

(74)
(Blank);

N-(1-Amino-1-oxo-3-phenylpropan-
18

2-yl)-1H-indazole-3-carboxamide with substitution on the
19

nitrogen atom of the indazole ring by alkyl, haloalkyl,
20

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
21

alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
22

2-(4-morpholinyl)ethyl, whether or not further substituted
23

on the indazole ring to any

extent: including, but not
24

limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;

25

(75)
(Blank);

N-(1-Amino-1-oxo-3-phenylpropan-
26

2-yl)-1H-indole-3-carboxamide with substitution on the

SB1773 Engrossed
- 68 -
LRB104 03029 RLC 13047 b
1

nitrogen atom of the indole ring by alkyl, haloalkyl,
2

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
3

alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
4

2-(4-morpholinyl)ethyl, whether or not further substituted
5

on the indazole ring to any extent: including, but not
6

limited to, APP-PICA and 5-fluoro-APP-PICA;

7

(76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
8

4-AcO-DMT;
9

(77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
10

name 5-MeO-MIPT;
11

(78) 4-hydroxy Diethyltryptamine (4-HO-DET);
12

(79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
13

(80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
14

(81) 4-hydroxy-N-methyl-N-isopropyltryptamine
15

(4-HO-MiPT);
16

(82)
(Blank);

Fluorophenylpiperazine;
17

(83) Methoxetamine;
18

(84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
19

ethcathinone).
20

(e) Unless specifically excepted or unless listed in
21
another schedule, any material, compound, mixture, or
22
preparation which contains any quantity of the following
23
substances having a depressant effect on the central nervous
24
system, including its salts, isomers, and salts of isomers
25
whenever the existence of such salts, isomers, and salts of
26
isomers is possible within the specific chemical designation:

SB1773 Engrossed
- 69 -
LRB104 03029 RLC 13047 b
1

(1) mecloqualone;
2

(2) methaqualone; and
3

(3) gamma hydroxybutyric acid.
4

(f) Unless specifically excepted or unless listed in
5
another schedule, any material, compound, mixture, or
6
preparation which contains any quantity of the following
7
substances having a stimulant effect on the central nervous
8
system, including its salts, isomers, and salts of isomers:
9

(1) Fenethylline;
10

(2) N-ethylamphetamine;
11

(3) Aminorex (some other names:

12

2-amino-5-phenyl-2-oxazoline; aminoxaphen;

13

4-5-dihydro-5-phenyl-2-oxazolamine) and its

14

salts, optical isomers, and salts of optical isomers;
15

(4) Methcathinone (some other names:

16

2-methylamino-1-phenylpropan-1-one;

17

Ephedrone; 2-(methylamino)-propiophenone;

18

alpha-(methylamino)propiophenone; N-methylcathinone;

19

methycathinone; Monomethylpropion; UR 1431) and its

20

salts, optical isomers, and salts of optical isomers;
21

(5) Cathinone (some trade or other names:

22

2-aminopropiophenone; alpha-aminopropiophenone;

23

2-amino-1-phenyl-propanone; norephedrone);
24

(6) N,N-dimethylamphetamine (also known as:

25

N,N-alpha-trimethyl-benzeneethanamine;

26

N,N-alpha-trimethylphenethylamine);

SB1773 Engrossed
- 70 -
LRB104 03029 RLC 13047 b
1

(7) (+ or -) cis-4-methylaminorex ((+ or -) cis-

2

4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
3

(8) 3,4-Methylenedioxypyrovalerone (MDPV);
4

(9) Halogenated amphetamines and

5

methamphetamines - any compound derived from either

6

amphetamine or methamphetamine through the substitution

7

of a halogen on the phenyl ring, including, but not

8

limited to, 2-fluoroamphetamine, 3-

9

fluoroamphetamine and 4-fluoroamphetamine;
10

(10) Aminopropylbenzofuran (APB):

11

including 4-(2-Aminopropyl) benzofuran, 5-

12

(2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)

13

benzofuran, and 7-(2-Aminopropyl) benzofuran;
14

(11) Aminopropyldihydrobenzofuran (APDB):

15

including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,

16

5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,

17

6-(2-Aminopropyl)-2,3-dihydrobenzofuran,

18

and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran;
19

(12) Methylaminopropylbenzofuran

20

(MAPB): including 4-(2-methylaminopropyl)

21

benzofuran, 5-(2-methylaminopropyl)benzofuran,

22

6-(2-methylaminopropyl)benzofuran

23

and 7-(2-methylaminopropyl)benzofuran
;

.

24

(13) Methylaminopropyldihydrobenzofuran

25

(MAPDB): including 1-(2,3-dihydrobenzofuran-5-yl)-

26

N-methylpropan-2-amine.

SB1773 Engrossed
- 71 -
LRB104 03029 RLC 13047 b
1

(g) Temporary listing of substances subject to emergency
2
scheduling. Any material, compound, mixture, or preparation
3
that contains any quantity of the following substances:
4

(1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
5

(benzylfentanyl), its optical isomers, isomers, salts, and
6

salts of isomers;
7

(2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
8

phenylpropanamide (thenylfentanyl), its optical isomers,
9

salts, and salts of isomers.
10

(h) Synthetic cathinones. Unless specifically excepted,
11
any chemical compound which is not approved by the United
12
States Food and Drug Administration or, if approved, is not
13
dispensed or possessed in accordance with State or federal
14
law, not including bupropion, structurally derived from
15
2-aminopropan-1-one by substitution at the 1-position with
16
either phenyl, naphthyl, or thiophene ring systems, whether or
17
not the compound is further modified in one or more of the
18
following ways:
19

(1) by substitution in the ring system to any extent
20

with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
21

halide substituents, whether or not further substituted in
22

the ring system by one or more other univalent
23

substituents. Examples of this class include, but are not
24

limited to, 3,4-Methylenedioxycathinone (bk-MDA);
25

(2) by substitution at the 3-position with an acyclic
26

alkyl substituent. Examples of this class include, but are

SB1773 Engrossed
- 72 -
LRB104 03029 RLC 13047 b
1

not limited to, 2-methylamino-1-phenylbutan-1-one
2

(buphedrone); or
3

(3) by substitution at the 2-amino nitrogen atom with
4

alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
5

inclusion of the 2-amino nitrogen atom in a cyclic
6

structure. Examples of this class include, but are not
7

limited to, Dimethylcathinone, Ethcathinone, and
8

a-Pyrrolidinopropiophenone (a-PPP); or
9

Any other synthetic cathinone which is not approved by the
10
United States Food and Drug Administration or, if approved, is
11
not dispensed or possessed in accordance with State or federal
12
law.
13

(i) Synthetic cannabinoids or piperazines. Any synthetic
14
cannabinoid or piperazine which is not approved by the United
15
States Food and Drug Administration or, if approved, which is
16
not dispensed or possessed in accordance with State and
17
federal law.
18

(1) As used in this Section, "synthetic cannabinoid"
19

includes, but is not limited to, any compound, as
20

identified in a report from an accredited forensic
21

laboratory, that is structurally derived from any one or
22

more of the following compounds:
23

(A) Any compound structurally derived from
24

3-(1-naphthoyl)indole or
25

1H-indol-3-yl-(1-naphthyl)methane by substitution at
26

the nitrogen atom of the indole ring by alkyl,

SB1773 Engrossed
- 73 -
LRB104 03029 RLC 13047 b
1

haloalkyl, alkenyl, cycloalkylmethyl,
2

cycloalkylethyl, aryl halide, alkyl aryl halide,
3

1-(N-methyl-2-piperidinyl)methyl, or
4

2-(4-morpholinyl)ethyl whether or not further
5

substituted in the indole ring to any extent, whether
6

or not substituted in the naphthyl ring to any extent.
7

Examples of this structural class include, but are not
8

limited to, JWH-018, AM-2201, JWH-175, JWH-184, and
9

JWH-185;
10

(B) 3-(1-naphthoyl)pyrrole by substitution at the
11

nitrogen atom of the pyrrole ring by alkyl, haloalkyl,
12

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
13

halide, alkyl aryl halide,
14

1-(N-methyl-2-piperidinyl)methyl, or
15

2-(4-morpholinyl)ethyl, whether or not further
16

substituted in the pyrrole ring to any extent, whether
17

or not substituted in the naphthyl ring to any extent.
18

Examples of this structural class include, but are not
19

limited to, JWH-030, JWH-145, JWH-146, JWH-307, and
20

JWH-368;
21

(C) 1-(1-naphthylmethyl)indene by substitution at
22

the 3-position of the indene ring by alkyl, haloalkyl,
23

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
24

halide, alkyl aryl halide,
25

1-(N-methyl-2-piperidinyl)methyl, or
26

2-(4-morpholinyl)ethyl whether or not further

SB1773 Engrossed
- 74 -
LRB104 03029 RLC 13047 b
1

substituted in the indene ring to any extent, whether
2

or not substituted in the naphthyl ring to any extent.
3

Examples of this structural class include, but are not
4

limited to, JWH-176;
5

(D) 3-phenylacetylindole by substitution at the
6

nitrogen atom of the indole ring with alkyl,
7

haloalkyl, alkenyl, cycloalkylmethyl,
8

cycloalkylethyl, aryl halide, alkyl aryl halide,
9

1-(N-methyl-2-piperidinyl)methyl, or
10

2-(4-morpholinyl)ethyl, whether or not further
11

substituted in the indole ring to any extent, whether
12

or not substituted in the phenyl ring to any extent.
13

Examples of this structural class include, but are not
14

limited to, JWH-167, JWH-250, JWH-251, and RCS-8;
15

(E) 2-(3-hydroxycyclohexyl)phenol by substitution
16

at the 5-position of the phenolic ring by alkyl,
17

haloalkyl, alkenyl, cycloalkylmethyl,
18

cycloalkylethyl, aryl halide, alkyl aryl halide,
19

1-(N-methyl-2-piperidinyl)methyl, or
20

2-(4-morpholinyl)ethyl, whether or not substituted in
21

the cyclohexyl ring to any extent. Examples of this
22

structural class include, but are not limited to, CP
23

47, 497 and its C8 homologue (cannabicyclohexanol);
24

(F) 3-(benzoyl) indole with substitution at the
25

nitrogen atom of the indole ring by an alkyl,
26

haloalkyl, alkenyl, cycloalkylmethyl,

SB1773 Engrossed
- 75 -
LRB104 03029 RLC 13047 b
1

cycloalkylethyl, aryl halide, alkyl aryl halide,
2

1-(N-methyl-2-piperidinyl)methyl, or
3

2-(4-morpholinyl)ethyl group whether or not further
4

substituted in the indole ring to any extent and
5

whether or not substituted in the phenyl ring to any
6

extent. Examples of this structural class include, but
7

are not limited to, AM-630, AM-2233, AM-694,
8

Pravadoline (WIN 48,098), and RCS-4;
9

(G) 3-cyclopropoylindole with substitution at the
10

nitrogen atom of the indole ring by alkyl, haloalkyl,
11

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
12

halide, alkyl aryl halide,
13

1-(N-methyl-2-piperidinyl)methyl, or
14

2-(4-morpholinyl)ethyl, whether or not further
15

substituted on the indole ring to any extent, whether
16

or not substituted on the cyclopropyl ring to any
17

extent, including, but not limited to, XLR11, UR144,
18

FUB-144;
19

(H) 3-adamantoylindole with substitution at the
20

nitrogen atom of the indole ring by alkyl, haloalkyl,
21

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
22

halide, alkyl aryl halide,
23

1-(N-methyl-2-piperidinyl)methyl, or
24

2-(4-morpholinyl)ethyl, whether or not further
25

substituted on the indole ring to any extent, whether
26

or not substituted on the adamantyl ring to any

SB1773 Engrossed
- 76 -
LRB104 03029 RLC 13047 b
1

extent, including, but not limited to, AB-001;
2

(I) N-(adamantyl)-indole-3-carboxamide with
3

substitution at the nitrogen atom of the indole ring
4

by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
5

cycloalkylethyl, aryl halide, alkyl aryl halide,
6

1-(N-methyl-2-piperidinyl)methyl, or
7

2-(4-morpholinyl)ethyl, whether or not further
8

substituted on the indole ring to any extent, whether
9

or not substituted on the adamantyl ring to any
10

extent, including, but not limited to, APICA/2NE-1,
11

STS-135;
12

(J) N-(adamantyl)-indazole-3-carboxamide with
13

substitution at a nitrogen atom of the indazole ring
14

by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
15

cycloalkylethyl, aryl halide, alkyl aryl halide,
16

1-(N-methyl-2-piperidinyl)methyl, or
17

2-(4-morpholinyl)ethyl, whether or not further
18

substituted on the indazole ring to any extent,
19

whether or not substituted on the adamantyl ring to
20

any extent, including, but not limited to, AKB48,
21

5F-AKB48;
22

(K) 1H-indole-3-carboxylic acid 8-quinolinyl ester
23

with substitution at the nitrogen atom of the indole
24

ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
25

cycloalkylethyl, aryl halide, alkyl aryl halide,
26

1-(N-methyl-2-piperidinyl)methyl, or

SB1773 Engrossed
- 77 -
LRB104 03029 RLC 13047 b
1

2-(4-morpholinyl)ethyl, whether or not further
2

substituted on the indole ring to any extent, whether
3

or not substituted on the quinoline ring to any
4

extent, including, but not limited to, PB22, 5F-PB22,
5

FUB-PB-22;
6

(L) 3-(1-naphthoyl)indazole with substitution at
7

the nitrogen atom of the indazole ring by alkyl,
8

haloalkyl, alkenyl, cycloalkylmethyl,
9

cycloalkylethyl, aryl halide, alkyl aryl halide,
10

1-(N-methyl-2-piperidinyl)methyl, or
11

2-(4-morpholinyl)ethyl, whether or not further
12

substituted on the indazole ring to any extent,
13

whether or not substituted on the naphthyl ring to any
14

extent, including, but not limited to, THJ-018,
15

THJ-2201;
16

(M) 2-(1-naphthoyl)benzimidazole with
17

substitution at the nitrogen atom of the benzimidazole
18

ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
19

cycloalkylethyl, aryl halide, alkyl aryl halide,
20

1-(N-methyl-2-piperidinyl)methyl, or
21

2-(4-morpholinyl)ethyl, whether or not further
22

substituted on the benzimidazole ring to any extent,
23

whether or not substituted on the naphthyl ring to any
24

extent, including, but not limited to, FUBIMINA;
25

(N) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-
26

indazole-3-carboxamide with substitution on the

SB1773 Engrossed
- 78 -
LRB104 03029 RLC 13047 b
1

nitrogen atom of the indazole ring by alkyl,
2

haloalkyl, alkenyl, cycloalkylmethyl,
3

cycloalkylethyl, aryl halide, alkyl aryl halide,
4

1-(N-methyl-2-piperidinyl)methyl, or
5

2-(4-morpholinyl)ethyl, whether or not further
6

substituted on the indazole ring to any extent,
7

including, but not limited to, AB-PINACA, AB-FUBINACA,
8

AB-CHMINACA;
9

(O) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-
10

1H-indazole-3-carboxamide with substitution on the
11

nitrogen atom of the indazole ring by alkyl,
12

haloalkyl, alkenyl, cycloalkylmethyl,
13

cycloalkylethyl, aryl halide, alkyl aryl halide,
14

1-(N-methyl-2-piperidinyl)methyl, or
15

2-(4-morpholinyl)ethyl, whether or not further
16

substituted on the indazole ring to any extent,
17

including, but not limited to, ADB-PINACA,
18

ADB-FUBINACA;
19

(P) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-
20

1H-indole-3-carboxamide with substitution on the
21

nitrogen atom of the indole ring by alkyl, haloalkyl,
22

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
23

halide, alkyl aryl halide,
24

1-(N-methyl-2-piperidinyl)methyl, or
25

2-(4-morpholinyl)ethyl, whether or not further
26

substituted on the indole ring to any extent,

SB1773 Engrossed
- 79 -
LRB104 03029 RLC 13047 b
1

including, but not limited to, ADBICA, 5F-ADBICA;
2

(Q) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-
3

indole-3-carboxamide with substitution on the nitrogen
4

atom of the indole ring by alkyl, haloalkyl, alkenyl,
5

cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
6

aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
7

2-(4-morpholinyl)ethyl, whether or not further
8

substituted on the indole ring to any extent,
9

including, but not limited to, ABICA, 5F-ABICA;
10

(R) Methyl 2-(1H-indazole-3-carboxamido)-
11

3-methylbutanoate with substitution on the nitrogen
12

atom of the indazole ring by alkyl, haloalkyl,
13

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
14

halide, alkyl aryl halide,
15

1-(N-methyl-2-piperidinyl)methyl, or
16

2-(4-morpholinyl)ethyl, whether or not further
17

substituted on the indazole ring to any extent,
18

including, but not limited to, AMB, 5F-AMB;
19

(S) Methyl 2-(1H-indazole-3-carboxamido)-
20

3,3-dimethylbutanoate with substitution on the
21

nitrogen atom of the indazole ring by alkyl,
22

haloalkyl, alkenyl, cycloalkylmethyl,
23

cycloalkylethyl, aryl halide, alkyl aryl halide,
24

1-(N-methyl-2-piperidinyl)methyl, or
25

2-(4-morpholinyl)ethyl, whether or not further
26

substituted on the indazole ring to any extent,

SB1773 Engrossed
- 80 -
LRB104 03029 RLC 13047 b
1

including, but not limited to, 5-fluoro-MDMB-PINACA,
2

MDMB-FUBINACA;
3

(T) Methyl 2-(1H-indole-3-carboxamido)-3-
4

methylbutanoate with substitution on the nitrogen atom
5

of the indole ring by alkyl, haloalkyl, alkenyl,
6

cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
7

aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
8

2-(4-morpholinyl)ethyl, whether or not further
9

substituted on the indole ring to any extent,
10

including, but not limited to, MMB018, MMB2201, and
11

AMB-CHMICA;
12

(U) Methyl 2-(1H-indole-3-carboxamido)-3,3-
13

dimethylbutanoate with substitution on the nitrogen
14

atom of the indole ring by alkyl, haloalkyl, alkenyl,
15

cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
16

aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
17

2-(4-morpholinyl)ethyl, whether or not further
18

substituted on the indazole indole ring to any extent,
19

including, but not limited to, MDMB-CHMICA;
20

(V) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
21

indazole-3-carboxamide with substitution on the
22

nitrogen atom of the indazole ring by alkyl,
23

haloalkyl, alkenyl, cycloalkylmethyl,
24

cycloalkylethyl, aryl halide, alkyl aryl halide,
25

1-(N-methyl-2-piperidinyl)methyl, or
26

2-(4-morpholinyl)ethyl, whether or not further

SB1773 Engrossed
- 81 -
LRB104 03029 RLC 13047 b
1

substituted on the indazole ring to any extent,
2

including, but not limited to, APP-CHMINACA,
3

5-fluoro-APP-PINACA;
4

(W) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-
5

1H-indole-3-carboxamide with substitution on the
6

nitrogen atom of the indole ring by alkyl, haloalkyl,
7

alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
8

halide, alkyl aryl halide,
9

1-(N-methyl-2-piperidinyl)methyl, or
10

2-(4-morpholinyl)ethyl, whether or not further
11

substituted on the indole ring to any extent,
12

including, but not limited to, APP-PICA and
13

5-fluoro-APP-PICA;
14

(X) 1H-indazole-3-carboxylic acid 8-quinolinyl
15

ester with substitution at the nitrogen atom of the
16

indazole ring by alkyl, haloalkyl, alkenyl,
17

cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
18

aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
19

2-(4-morpholinyl)ethyl, whether or not further
20

substituted on the inazdole ring to any extent,
21

whether or not substituted on the quinoline ring to
22

any extent, including, but not limited to, SDB-005,
23

5-F-SDB-005;
24

(2) As used in this Section, "synthetic piperazine"
25

includes, but is not limited to, any of the following
26

compounds and their positional isomers:

SB1773 Engrossed
- 82 -
LRB104 03029 RLC 13047 b
1

(A) N-Benzylpiperazine (BZP);
2

(B) Trifluoromethylphenylpiperazine (TFMPP);
3

(C) Fluorophenylpiperazine;
4

(D) Chlorophenylpiperazine.

5

(j) Unless specifically excepted or listed in another
6
schedule, any chemical compound which is not approved by the
7
United States Food and Drug Administration or, if approved, is
8
not dispensed or possessed in accordance with State or federal
9
law, and is derived from the following structural classes and
10
their salts:
11

(1) Benzodiazepine class: A fused 1,4-diazepine and
12

benzene ring structure with a phenyl connected to the
13

1,4-diazepine ring, with any substitution(s) or
14

replacement(s) on the 1,4-diazepine or benzene ring, any
15

substitution(s) on the phenyl ring, or any combination
16

thereof. Examples of this class include but are not
17

limited to: Clonazolam, Flualprazolam; or
18

(2) Thienodiazepine class: A fused 1,4-diazepine and
19

thiophene ring structure with a phenyl connected to the
20

1,4-diazepine ring, with any substitution(s) or
21

replacement(s) on the 1,4-diazepine or thiophene ring, any
22

substitution(s) on the phenyl ring, or any combination
23

thereof. Examples of this class include but are not
24

limited to: Etizolam.
25

(k) Fentanyl-related substances.
26

(1) As used in this Section, "fentanyl-related

SB1773 Engrossed
- 83 -
LRB104 03029 RLC 13047 b
1

substance" means any compound, as identified in a report
2

from an accredited forensic laboratory, unless
3

specifically excepted or listed under another schedule,
4

that is not approved by the United States Food and Drug
5

Administration or, if approved, is not dispensed or
6

possessed in accordance with State or federal law and that
7

is structurally derived from fentanyl
8

(N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)-
9

propanamide) by one or more of the following
10

modifications:
11

(A) replacement of the phenyl portion of the
12

phenethyl group by any monocycle, whether or not
13

further substituted in or on the monocycle;
14

(B) substitution in or on the phenethyl group with
15

alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl,
16

amino, or nitro groups;
17

(C) substitution in or on the piperidine ring with
18

alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo,
19

haloalkyl, amino, or nitro groups;
20

(D) replacement of the aniline ring with any
21

aromatic monocycle whether or not further substituted
22

in or on the aromatic monocycle; or
23

(E) replacement of the N-propionyl group by
24

another acyl group.
25

(2) "Fentanyl-related substance" includes, but is not
26

limited to, the following substances:

SB1773 Engrossed
- 84 -
LRB104 03029 RLC 13047 b
1

(A) Acetyl-alpha-methylfentanyl;
2

(B) Alpha-methylfentanyl (N-(1-alpha-methyl-beta-
3

phenyl)ethyl-4-piperidyl) propionanilide;
4

1-(1-methyl-2-phenylethyl)-4-(N-propanilido)
5

piperidine;
6

(C) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-
7

thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
8

(D) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-
9

phenethyl)-4-piperidinyl]-N-phenylpropanamide
10

(E) 3-Methylfentanyl (N-[3-methyl-1-(2-
11

phenylethyl)-4-piperidyl]-N-phenylpropanamide);
12

(F) 3-Methylthiofentanyl (N-[(3-methyl-1-
13

(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
14

(G) Para-fluorofentanyl (N-(4-fluorophenyl)-
15

N-[1-(2-phenethyl)-4-piperidinyl]propanamide);
16

(H) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-
17

4-piperidinyl]-propanamide);
18

(I) Beta-hydroxy-3-methylfentanyl (other name:
19

N-[1-(2-hydroxy-2-phenethyl)-3-methyl-
20

4-piperidinyl]-N-phenylpropanamide);
21

(J) Furanyl fentanyl (FU-F);
22

(K) Butyryl fentanyl;
23

(L) Valeryl fentanyl;
24

(M) Acetyl fentanyl;
25

(N) Beta-hydroxy-thiofentanyl;
26

(O) Acrylfentanyl (acryloylfentanyl);

SB1773 Engrossed
- 85 -
LRB104 03029 RLC 13047 b
1

(P) Cyclopropyl fentanyl;
2

(Q) Crotonyl fentanyl;
3

(R) Methoxyacetyl fentanyl;
4

(S) Pentanoyl fentanyl;
5

(T) Cyclopentyl fentanyl;
6

(U) Isobutyryl fentanyl;
7

(V) Benzodioxolefentanyl;
8

(W) Tetrahydrofuran fentanyl.

9
(Source: P.A. 103-245, eff. 1-1-24
.)

10

(720 ILCS 570/206)

(from Ch. 56 1/2, par. 1206)
11

Sec. 206.
(a) The controlled substances listed in this
12
Section are included in Schedule II.
13

(b) Unless specifically excepted or unless listed in
14
another schedule, any of the following substances whether
15
produced directly or indirectly by extraction from substances
16
of vegetable origin, or independently by means of chemical
17
synthesis, or by combination of extraction and chemical
18
synthesis:
19

(1) Opium and opiates, and any salt, compound,
20

derivative or preparation of opium or opiate, excluding
21

apomorphine, dextrorphan, levopropoxyphene, nalbuphine,
22

nalmefene, naloxone, and naltrexone, and their respective
23

salts, but including the following:
24

(i) Raw Opium;
25

(ii) Opium extracts;

SB1773 Engrossed
- 86 -
LRB104 03029 RLC 13047 b
1

(iii) Opium fluid extracts;
2

(iv) Powdered opium;
3

(v) Granulated opium;
4

(vi) Tincture of opium;
5

(vii) Codeine;
6

(viii) Ethylmorphine;
7

(ix) Etorphine Hydrochloride;
8

(x) Hydrocodone;
9

(xi) Hydromorphone;
10

(xii) Metopon;
11

(xiii) Morphine;
12

(xiii.5) 6-Monoacetylmorphine;
13

(xiv) Oxycodone;
14

(xv) Oxymorphone;
15

(xv.5) Tapentadol;
16

(xvi) Thebaine;
17

(xvii) Thebaine-derived butorphanol.
18

(xviii) Methorphan, except drug products
19

containing dextromethorphan that may be dispensed
20

pursuant to a prescription order of a practitioner and
21

are sold in compliance with the safety and labeling
22

standards as set forth by the United States Food and
23

Drug Administration, or drug products containing
24

dextromethorphan that are sold in solid, tablet,
25

liquid, capsule, powder, thin film, or gel form and
26

which are formulated, packaged, and sold in dosages

SB1773 Engrossed
- 87 -
LRB104 03029 RLC 13047 b
1

and concentrations for use as an over-the-counter drug
2

product. For the purposes of this Section,
3

"over-the-counter drug product" means a drug that is
4

available to consumers without a prescription and sold
5

in compliance with the safety and labeling standards
6

as set forth by the United States Food and Drug
7

Administration.
8

(2) Any salt, compound, isomer, derivative or
9

preparation thereof which is chemically equivalent or
10

identical with any of the substances referred to in
11

subparagraph (1), but not including the isoquinoline
12

alkaloids of opium;
13

(3) Opium poppy and poppy straw;
14

(4) Coca leaves and any salt, compound, isomer, salt
15

of an isomer, derivative, or preparation of coca leaves
16

including cocaine or ecgonine, and any salt, compound,
17

isomer, derivative, or preparation thereof which is
18

chemically equivalent or identical with any of these
19

substances, but not including decocainized coca leaves or
20

extractions of coca leaves which do not contain cocaine or
21

ecgonine (for the purpose of this paragraph, the term
22

"isomer" includes optical
, positional
and geometric
23

isomers);
24

(5) Concentrate of poppy straw (the crude extract of
25

poppy straw in either liquid, solid or powder form which
26

contains the phenanthrine alkaloids of the opium poppy).

SB1773 Engrossed
- 88 -
LRB104 03029 RLC 13047 b
1

(c) Unless specifically excepted or unless listed in
2
another schedule any of the following opiates, including their
3
isomers, esters, ethers, salts, and salts of isomers, whenever
4
the existence of these isomers, esters, ethers and salts is
5
possible within the specific chemical designation, dextrorphan
6
excepted:
7

(1) Alfentanil;
8

(1.1) Carfentanil;
9

(1.2) Thiafentanyl;
10

(2) Alphaprodine;
11

(3) Anileridine;
12

(4) Bezitramide;
13

(5) Bulk Dextropropoxyphene (non-dosage forms);
14

(6) Dihydrocodeine;
15

(7) Diphenoxylate;
16

(8) Fentanyl;
17

(9) Sufentanil;
18

(9.5) Remifentanil;
19

(10) Isomethadone;
20

(11) (Blank);
21

(12) Levorphanol (Levorphan);
22

(13) Metazocine;
23

(14) Methadone;
24

(15) Methadone-Intermediate,

25

4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
26

(16) Moramide-Intermediate,

SB1773 Engrossed
- 89 -
LRB104 03029 RLC 13047 b
1

2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic

2

acid;
3

(17) Pethidine (meperidine);
4

(18) Pethidine-Intermediate-A,

5

4-cyano-1-methyl-4-phenylpiperidine;
6

(19) Pethidine-Intermediate-B,

7

ethyl-4-phenylpiperidine-4-carboxylate;
8

(20) Pethidine-Intermediate-C,

9

1-methyl-4-phenylpiperidine-4-carboxylic acid;
10

(21) Phenazocine;
11

(22) Piminodine;
12

(23) Racemethorphan;
13

(24) (Blank);
14

(25) Levo-alphacetylmethadol (some other names:
15

levo-alpha-acetylmethadol, levomethadyl acetate, LAAM).
16

(d) Unless specifically excepted or unless listed in
17
another schedule, any material, compound, mixture, or
18
preparation which contains any quantity of the following
19
substances having a stimulant effect on the central nervous
20
system:
21

(1) Amphetamine, its salts, optical isomers, and salts
22

of its optical isomers;
23

(2) Methamphetamine, its salts, isomers, and salts of
24

its isomers;
25

(3) Phenmetrazine and its salts;
26

(4) Methylphenidate;

SB1773 Engrossed
- 90 -
LRB104 03029 RLC 13047 b
1

(5) Lisdexamfetamine.
2

(e) Unless specifically excepted or unless listed in
3
another schedule, any material, compound, mixture, or
4
preparation which contains any quantity of the following
5
substances having a depressant effect on the central nervous
6
system, including its salts, isomers, and salts of isomers
7
whenever the existence of such salts, isomers, and salts of
8
isomers is possible within the specific chemical designation:
9

(1) Amobarbital;
10

(2) Secobarbital;
11

(3) Pentobarbital;
12

(4) Pentazocine;
13

(5) Phencyclidine;
14

(6) Gluthethimide;
15

(7) (Blank).
16

(f) Unless specifically excepted or unless listed in
17
another schedule, any material, compound, mixture, or
18
preparation which contains any quantity of the following
19
substances:
20

(1) Immediate precursor to amphetamine and
21

methamphetamine:
22

(i) Phenylacetone
23

Some trade or other names: phenyl-2-propanone;
24

P2P; benzyl methyl ketone; methyl benzyl ketone.
25

(2) Immediate precursors to phencyclidine:
26

(i) 1-phenylcyclohexylamine;

SB1773 Engrossed
- 91 -
LRB104 03029 RLC 13047 b
1

(ii) 1-piperidinocyclohexanecarbonitrile (PCC).
2

(3) Nabilone.
3
(Source: P.A. 100-368, eff. 1-1-18
.)

4

(720 ILCS 570/208)

(from Ch. 56 1/2, par. 1208)
5

(Text of Section before amendment by P.A. 103-881
)
6

Sec. 208.
(a) The controlled substances listed in this
7
Section are included in Schedule III.
8

(b) Unless specifically excepted or unless listed in
9
another schedule, any material, compound, mixture, or
10
preparation which contains any quantity of the following
11
substances having a stimulant effect on the central nervous
12
system, including its salts, isomers (whether optical
13
position, or geometric), and salts of such isomers whenever
14
the existence of such salts, isomers, and salts of isomers is
15
possible within the specific chemical designation;
16

(1) Those compounds, mixtures, or preparations in
17

dosage unit form containing any stimulant substances
18

listed in Schedule II which compounds, mixtures, or
19

preparations were listed on August 25, 1971, as excepted
20

compounds under Title 21, Code of Federal Regulations,
21

Section 308.32, and any other drug of the quantitative
22

composition shown in that list for those drugs or which is
23

the same except that it contains a lesser quantity of
24

controlled substances;
25

(2) Benzphetamine;

SB1773 Engrossed
- 92 -
LRB104 03029 RLC 13047 b
1

(3) Chlorphentermine;
2

(4) Clortermine;
3

(5) Phendimetrazine.
4

(c) Unless specifically excepted or unless listed in
5
another schedule, any material, compound, mixture, or
6
preparation which contains any quantity of the following
7
substances having a potential for abuse associated with a
8
depressant effect on the central nervous system:
9

(1) Any compound, mixture, or preparation containing
10

amobarbital, secobarbital, pentobarbital or any salt
11

thereof and one or more other active medicinal ingredients
12

which are not listed in any schedule;
13

(2) Any suppository dosage form containing
14

amobarbital, secobarbital, pentobarbital or any salt of
15

any of these drugs and approved by the Federal Food and
16

Drug Administration for marketing only as a suppository;
17

(3) Any substance which contains any quantity of a
18

derivative of barbituric acid, or any salt thereof:
19

(3.1) Aprobarbital;
20

(3.2) Butabarbital (secbutabarbital);
21

(3.3) Butalbital;
22

(3.4) Butobarbital (butethal);
23

(4) Chlorhexadol;
24

(5) Methyprylon;
25

(6) Sulfondiethylmethane;
26

(7) Sulfonethylmethane;

SB1773 Engrossed
- 93 -
LRB104 03029 RLC 13047 b
1

(8) Sulfonmethane;
2

(9) Lysergic acid;
3

(10) Lysergic acid amide;
4

(10.1) Tiletamine or zolazepam or both, or any salt of
5

either of them.
6

Some trade or other names for a tiletamine-zolazepam

7

combination product: Telazol.

8

Some trade or other names for Tiletamine:

9

2-(ethylamino)-2-(2-thienyl)-cyclohexanone.

10

Some trade or other names for zolazepam:

11

4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-

12

[3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon.
13

(11) Any material, compound, mixture or preparation
14

containing not more than 12.5 milligrams of pentazocine or
15

any of its salts, per 325 milligrams of aspirin;
16

(12) Any material, compound, mixture or preparation
17

containing not more than 12.5 milligrams of pentazocine or
18

any of its salts, per 325 milligrams of acetaminophen;
19

(13) Any material, compound, mixture or preparation
20

containing not more than 50 milligrams of pentazocine or
21

any of its salts plus naloxone HCl USP 0.5 milligrams, per
22

dosage unit;
23

(14) Ketamine;
24

(15) Thiopental.
25

(d) Nalorphine.
26

(d.5) Buprenorphine.

SB1773 Engrossed
- 94 -
LRB104 03029 RLC 13047 b
1

(e) Unless specifically excepted or unless listed in
2
another schedule, any material, compound, mixture, or
3
preparation containing limited quantities of any of the
4
following narcotic drugs, or their salts calculated as the
5
free anhydrous base or alkaloid, as set forth below:
6

(1) not more than 1.8 grams of codeine per 100
7

milliliters or not more than 90 milligrams per dosage
8

unit, with an equal or greater quantity of an isoquinoline
9

alkaloid of opium;
10

(2) not more than 1.8 grams of codeine per 100
11

milliliters or not more than 90 milligrams per dosage
12

unit, with one or more active non-narcotic ingredients in
13

recognized therapeutic amounts;
14

(3) (blank);
15

(4) (blank);
16

(5) not more than 1.8 grams of dihydrocodeine per 100
17

milliliters or not more than 90 milligrams per dosage
18

unit, with one or more active, non-narcotic ingredients in
19

recognized therapeutic amounts;
20

(6) not more than 300 milligrams of ethylmorphine per
21

100 milliliters or not more than 15 milligrams per dosage
22

unit, with one or more active, non-narcotic ingredients in
23

recognized therapeutic amounts;
24

(7) not more than 500 milligrams of opium per 100
25

milliliters or per 100 grams, or not more than 25
26

milligrams per dosage unit, with one or more active,

SB1773 Engrossed
- 95 -
LRB104 03029 RLC 13047 b
1

non-narcotic ingredients in recognized therapeutic
2

amounts;
3

(8) not more than 50 milligrams of morphine per 100
4

milliliters or per 100 grams with one or more active,
5

non-narcotic ingredients in recognized therapeutic
6

amounts.
7

(f) Anabolic steroids, except the following anabolic
8
steroids that are exempt:
9

(1) Androgyn L.A.;
10

(2) Andro-Estro 90-4;
11

(3) depANDROGYN;
12

(4) DEPO-T.E.;
13

(5) depTESTROGEN;
14

(6) Duomone;
15

(7) DURATESTRIN;
16

(8) DUO-SPAN II;
17

(9) Estratest;
18

(10) Estratest H.S.;
19

(11) PAN ESTRA TEST;
20

(12) Premarin with Methyltestosterone;
21

(13) TEST-ESTRO Cypionates;
22

(14) Testosterone Cyp 50 Estradiol Cyp 2;
23

(15) Testosterone Cypionate-Estradiol Cypionate
24

injection; and
25

(16) Testosterone Enanthate-Estradiol Valerate
26

injection.

SB1773 Engrossed
- 96 -
LRB104 03029 RLC 13047 b
1

(g) Hallucinogenic substances.
2

(1) Dronabinol (synthetic) in sesame oil and
3

encapsulated in a soft gelatin capsule in a U.S. Food and
4

Drug Administration approved product. Some other names for
5

dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-
6

6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or
7

(-)-delta-9-(trans)-tetrahydrocannabinol.
8

(2) (Reserved).
9

(h) The Department may except by rule any compound,
10
mixture, or preparation containing any stimulant or depressant
11
substance listed in subsection (b) from the application of all
12
or any part of this Act if the compound, mixture, or
13
preparation contains one or more active medicinal ingredients
14
not having a stimulant or depressant effect on the central
15
nervous system, and if the admixtures are included therein in
16
combinations, quantity, proportion, or concentration that
17
vitiate the potential for abuse of the substances which have a
18
stimulant or depressant effect on the central nervous system.
19
(Source: P.A. 100-368, eff. 1-1-18
.)

20

(Text of Section after amendment by P.A. 103-881
)
21

Sec. 208.
(a) The controlled substances listed in this
22
Section are included in Schedule III.
23

(b) Unless specifically excepted or unless listed in
24
another schedule, any material, compound, mixture, or
25
preparation which contains any quantity of the following

SB1773 Engrossed
- 97 -
LRB104 03029 RLC 13047 b
1
substances having a stimulant effect on the central nervous
2
system, including its salts, isomers (whether optical
3
position, or geometric), and salts of such isomers whenever
4
the existence of such salts, isomers, and salts of isomers is
5
possible within the specific chemical designation;
6

(1) Those compounds, mixtures, or preparations in
7

dosage unit form containing any stimulant substances
8

listed in Schedule II which compounds, mixtures, or
9

preparations were listed on August 25, 1971, as excepted
10

compounds under Title 21, Code of Federal Regulations,
11

Section 308.32, and any other drug of the quantitative
12

composition shown in that list for those drugs or which is
13

the same except that it contains a lesser quantity of
14

controlled substances;
15

(2) Benzphetamine;
16

(3) Chlorphentermine;
17

(4) Clortermine;
18

(5) Phendimetrazine.
19

(c) Unless specifically excepted or unless listed in
20
another schedule, any material, compound, mixture, or
21
preparation which contains any quantity of the following
22
substances having a potential for misuse associated with a
23
depressant effect on the central nervous system:
24

(1) Any compound, mixture, or preparation containing
25

amobarbital, secobarbital, pentobarbital or any salt
26

thereof and one or more other active medicinal ingredients

SB1773 Engrossed
- 98 -
LRB104 03029 RLC 13047 b
1

which are not listed in any schedule;
2

(2) Any suppository dosage form containing
3

amobarbital, secobarbital, pentobarbital or any salt of
4

any of these drugs and approved by the Federal Food and
5

Drug Administration for marketing only as a suppository;
6

(3) Any substance which contains any quantity of a
7

derivative of barbituric acid, or any salt thereof:
8

(3.1) Aprobarbital;
9

(3.2) Butabarbital (secbutabarbital);
10

(3.3) Butalbital;
11

(3.4) Butobarbital (butethal);
12

(4) Chlorhexadol;
13

(5) Methyprylon;
14

(6) Sulfondiethylmethane;
15

(7) Sulfonethylmethane;
16

(8) Sulfonmethane;
17

(9) Lysergic acid;
18

(10) Lysergic acid amide;
19

(10.1) Tiletamine or zolazepam or both, or any salt of
20

either of them.
21

Some trade or other names for a tiletamine-zolazepam

22

combination product: Telazol.

23

Some trade or other names for Tiletamine:

24

2-(ethylamino)-2-(2-thienyl)-cyclohexanone.

25

Some trade or other names for zolazepam:

26

4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-

SB1773 Engrossed
- 99 -
LRB104 03029 RLC 13047 b
1

[3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon.
2

(11) Any material, compound, mixture or preparation
3

containing not more than 12.5 milligrams of pentazocine or
4

any of its salts, per 325 milligrams of aspirin;
5

(12) Any material, compound, mixture or preparation
6

containing not more than 12.5 milligrams of pentazocine or
7

any of its salts, per 325 milligrams of acetaminophen;
8

(13) Any material, compound, mixture or preparation
9

containing not more than 50 milligrams of pentazocine or
10

any of its salts plus naloxone HCl USP 0.5 milligrams, per
11

dosage unit;
12

(14) Ketamine;
13

(15) Thiopental
;

.

14

(16) Xylazine.

15

(d) Nalorphine.
16

(d.5) Buprenorphine.
17

(e) Unless specifically excepted or unless listed in
18
another schedule, any material, compound, mixture, or
19
preparation containing limited quantities of any of the
20
following narcotic drugs, or their salts calculated as the
21
free anhydrous base or alkaloid, as set forth below:
22

(1) not more than 1.8 grams of codeine per 100
23

milliliters or not more than 90 milligrams per dosage
24

unit, with an equal or greater quantity of an isoquinoline
25

alkaloid of opium;
26

(2) not more than 1.8 grams of codeine per 100

SB1773 Engrossed
- 100 -
LRB104 03029 RLC 13047 b
1

milliliters or not more than 90 milligrams per dosage
2

unit, with one or more active non-narcotic ingredients in
3

recognized therapeutic amounts;
4

(3) (blank);
5

(4) (blank);
6

(5) not more than 1.8 grams of dihydrocodeine per 100
7

milliliters or not more than 90 milligrams per dosage
8

unit, with one or more active, non-narcotic ingredients in
9

recognized therapeutic amounts;
10

(6) not more than 300 milligrams of ethylmorphine per
11

100 milliliters or not more than 15 milligrams per dosage
12

unit, with one or more active, non-narcotic ingredients in
13

recognized therapeutic amounts;
14

(7) not more than 500 milligrams of opium per 100
15

milliliters or per 100 grams, or not more than 25
16

milligrams per dosage unit, with one or more active,
17

non-narcotic ingredients in recognized therapeutic
18

amounts;
19

(8) not more than 50 milligrams of morphine per 100
20

milliliters or per 100 grams with one or more active,
21

non-narcotic ingredients in recognized therapeutic
22

amounts.
23

(f) Anabolic steroids, except the following anabolic
24
steroids that are exempt:
25

(1) Androgyn L.A.;
26

(2) Andro-Estro 90-4;

SB1773 Engrossed
- 101 -
LRB104 03029 RLC 13047 b
1

(3) depANDROGYN;
2

(4) DEPO-T.E.;
3

(5) depTESTROGEN;
4

(6) Duomone;
5

(7) DURATESTRIN;
6

(8) DUO-SPAN II;
7

(9) Estratest;
8

(10) Estratest H.S.;
9

(11) PAN ESTRA TEST;
10

(12) Premarin with Methyltestosterone;
11

(13) TEST-ESTRO Cypionates;
12

(14) Testosterone Cyp 50 Estradiol Cyp 2;
13

(15) Testosterone Cypionate-Estradiol Cypionate
14

injection; and
15

(16) Testosterone Enanthate-Estradiol Valerate
16

injection.
17

(g) Hallucinogenic substances.
18

(1) Dronabinol (synthetic) in sesame oil and
19

encapsulated in a soft gelatin capsule in a U.S. Food and
20

Drug Administration approved product. Some other names for
21

dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-
22

6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or
23

(-)-delta-9-(trans)-tetrahydrocannabinol.
24

(2) (Reserved).
25

(h) The Department may except by rule any compound,
26
mixture, or preparation containing any stimulant or depressant

SB1773 Engrossed
- 102 -
LRB104 03029 RLC 13047 b
1
substance listed in subsection (b) from the application of all
2
or any part of this Act if the compound, mixture, or
3
preparation contains one or more active medicinal ingredients
4
not having a stimulant or depressant effect on the central
5
nervous system, and if the admixtures are included therein in
6
combinations, quantity, proportion, or concentration that
7
vitiate the potential for misuse of the substances which have
8
a stimulant or depressant effect on the central nervous
9
system.
10
(Source: P.A. 103-881, eff. 1-1-25.)

11

(720 ILCS 570/309.1 new)
12

Sec. 309.1.
Xylazine exemptions.
Notwithstanding the
13
scheduling of xylazine as a Schedule III controlled substance,
14
xylazine shall not be considered a controlled substance when:
15

(1) used by licensed Illinois veterinarians dispensing
16

or prescribing for, or administering to, a nonhuman
17

species of a drug containing xylazine that has been
18

approved by the U.S. Food and Drug Administration;
19

(2) used by licensed Illinois veterinarians dispensing
20

or prescribing for, or administering to, a nonhuman
21

species that is permissible under the Federal Food, Drug,
22

and Cosmetic Act;
23

(3) manufactured, distributed, or used as an active
24

pharmaceutical ingredient for manufacturing an animal drug
25

approved under the Federal Food, Drug, and Cosmetic Act;

SB1773 Engrossed
- 103 -
LRB104 03029 RLC 13047 b
1

(4) used by a licensed certified euthanasia technician
2

employed by a certified euthanasia agency; or
3

(5) used by a wildlife biologist engaged in legal or
4

authorized fieldwork under the indirect supervision of a
5

veterinarian.

6

Section 95.
No acceleration or delay.
Where this Act makes
7
changes in a statute that is represented in this Act by text
8
that is not yet or no longer in effect (for example, a Section
9
represented by multiple versions), the use of that text does
10
not accelerate or delay the taking effect of (i) the changes
11
made by this Act or (ii) provisions derived from any other
12
Public Act.

13

Section 99.
Effective date.
This Act takes effect January
14
1, 2026.

Footer

Disclaimer

This site is maintained for the Illinois General Assembly by the
Legislative Information System, 705 Stratton Building, Springfield, Illinois 62706.

Contact ILGA Webmaster

ILGA.gov uses cookies to ensure you get the best experience on our website. By continuing to browse ILGA.gov you consent to our use of cookies.
Read About Cookies

ILGA.GOV

2026 ILGA.gov | All Rights Reserved |
ADA

|
Disclaimers
|
Learn

This site is maintained for the Illinois General Assembly by the
Legislative Information System, 705 Stratton Building, Springfield, Illinois 62706.
Contact ILGA Webmaster

ILGA.gov uses cookies to ensure you get the best experience on our website. By continuing to browse ILGA.gov you consent to our use of cookies.
Read About Cookies

ILGA.GOV

2026 ILGA.gov | All Rights Reserved |
ADA

|
Disclaimers
|
Learn